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Abstract 
A Disintegrin And Metalloproteases (ADAMs) represents a family of transmembrane 
proteins with a distinct multidomain structure including a metalloprotease, disintegrin, 
and cysteine-rich domain. These proteins function in adhesion, regulation of cell 
signaling by proteolysis of cell surface proteins and their receptors. ADAM-9 is a 
protease that cleaves membrane-bound proteins such as VCAM-1, TNF-α, as well as 
extracellular matrix proteins like fibronectin and laminin-111. ADAM-9 also contains 
adhesive domains that are involved in cell adhesion and migration. In human and 
murine melanoma, ADAM-9 is expressed by both tumor and stroma cells at the 
tumor-stroma border. The significance of this expression is however not clear. To 
explore the functional role of ADAM-9 produced by the host in melanoma 
progression, B16F1 murine melanoma cells were injected in the flank of Adam-9-/- 
and wild type animals. Tumors developed in Adam-9-/- mice were significantly larger 
compared to wild type animals and displayed significant increase in tumor cell 
proliferation accompanied by decrease in apoptosis. Using co-culture systems of 
primary fibroblasts and B16F1 melanoma cells, we could detect increased melanoma 
cell proliferation when cultured in the presence of supernatants from Adam-9-/- but 
not wild type fibroblasts. Among the proteins secreted in strongly enhanced amounts 
from Adam-9-/- fibroblasts, was tissue inhibitor of metalloproteinases-1 (TIMP-1). 
Neutralization of TIMP-1 in Adam-9-/- fibroblasts supernatant using specific antibodies 
abolished the induced B16F1 proliferation. Besides TIMP-1, soluble TNF-α and 
TNFR1 were also up-regulated in Adam-9-/- fibroblasts supernatants. Using various in 
vitro approaches, we could demonstrate that neutralization of TNF-α in Adam-9-/- 
fibroblast resulted in reduced B16F1 cell apoptosis. In addition, by RNA and 
proteomic analysis, we found altered expression of extracellular matrix proteins at the 
tumor-stroma border of tumors from Adam-9-/- animals compared to wild type, which 
likely contributes to the melanoma phenotype observed in Adam-9-/- animals. 
Interestingly, we identified collagen type I as a new substrate of ADAM-9. In 
summary, our results indicate that loss of ADAM-9 in stromal fibroblasts results in 
altered release of soluble factors, which in turn affect melanoma cell proliferation and 
apoptosis.  
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Zusammenfassung 
Die A Disintegrin and Metalloproteases (ADAMs) sind Transmembranproteine und 
weisen eine Multidomänen-Struktur mit einer Metalloprotease-, einer Disintegrin- und 
einer Cystein-reichen Domäne auf. ADAMs vermitteln Zelladhäsion und sind an 
zellulärer Signaltransduktion durch die Proteolyse von Oberflächenproteinen und 
deren Rezeptoren beteiligt. ADAM-9 ist eine aktive Protease, welche membran-
gebundene Proteine, wie z.B. VCAM-1 und TNF-α sowie Proteine der 
extrazelllulären Matrix wie Fibronectin und Laminin-111 prozessiert. ADAM-9 
vermittelt ebenfalls Zelladhäsion und -migration. In humanen und murinen 
Melanomen wurde gezeigt, dass ADAM-9 an der Tumor-Stroma-Grenze sowohl in 
stromalen als auch in Tumorzellen lokalisiert ist. Die Bedeutung der ADAM-9 
Expression für das Tumorwachstum ist unklar. Um die Funktion der Expression von 
ADAM-9 in Stromazellen für die Melanomentwicklung zu analysieren, wurden B16F1 
Melanomzellen in die Flanke von Adam-9-/- und Wildtyp Tieren injiziert. Tumore die in 
Adam-9-/- Mäusen entstanden, waren signifikant größer als die in Wildtyp-Tieren und 
wiesen eine signifikant erhöhte Tumorzellproliferation und eine erniedrigte Apoptose 
auf. In Kokultur-Systemen mit primären Fibroblasten und B16F1 Melanomzellen 
konnten wir eine erhöhte Proliferation der Melanomzellen durch Inkubation mit 
Überständen von Adam-9-/- Fibroblasten, aber nicht von Wildtyp-Zellen, feststellen. 
Wir konnten zeigen, dass Adam-9-/- Fibroblasten unter anderem erhöhte Menge des 
TIMP-1 (tissue inhibitor of metalloproteinases) sekretieren. Die Neutralisation von 
TIMP-1 in Überständen von Adam-9-/- Fibroblasten durch spezifische Antikörper 
führte zur aufhebung der erhöhten Proliferation der Melanom Zellen. Neben TIMP-1 
waren auch lösliches TNF-α (tumornekrosefaktor-α) und TNFR1 erhöht in 
Überständen von Adam-9-/- Fibroblasten nachzuweisen. Durch verschiedene in vitro 
Experimente konnten wir zeigen, dass die Neutralisation von TNF-α in Adam-9-/- 
Fibroblasten zu einer reduzierten Apoptose der B16F1 Zellen führt. Zusätzlich 
konnten wir mit Hilfe von RNA- und Proteomarrays eine veränderte Expression von 
Proteinen der extrazellluären Matrix in der Tumor-Stroma-Grenze von Adam-9-/- im 
Vergleich zu Wildtyp-Tieren feststellen. Diese Veränderungen könnten zu erhöhte 
Tumorwachstum in Adam-9-/- Tieren beitragen. Interessanterweise konnten wir 
Kollagen Typ I als neues Substrat für ADAM-9 identifizieren. Zusammenfassend 
haben unsere Ergebnisse gezeigt, dass der Verlust von ADAM-9 in stromalen 
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Fibroblasten zu einer veränderten Freisetzung löslicher Faktoren führt, welche die 
Melanomzellproliferation und- apoptose beeinflussen.  
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1 Introduction 
1.1 Malignant melanoma  
1.1.1 Origin of melanoma  
Melanoma is the most serious form of skin cancer that originates from melanocytes 
(Bandarchi et al., 2010). During embryonic development, melanocytes from the 
neural-crest migrate into the skin where their survival, proliferation and differentiation 
are under control of several tissue factors (Herlyn et al., 2000). Gene mutations, 
altered production of growth factors and loss of adhesion molecules, contribute to the 
disruption of pathways involved in the regulation of melanocytes homeostasis and 
lead to malignant transformation (Schopfer et al., 2007). One of the initial events of 
transformation is the loss of intercellular contacts with keratinocytes, which release 
melanocytes from the regulatory control of these cells; this is followed by increased 
melanocyte proliferation and formation of nevus. Nevi are regarded as benign 
formations. Malignant transformation of melanocytes or nevi leads to exponential 
growth within the epidermis, also known as radial-growth-phase (RGP) melanoma. 
From the RGP, melanoma can invade the underlying dermal tissue thus initiating the 
vertical-growth-phase (VGP) ultimately leading to metastatic spread (figure 1) 
(Schopfer et al., 2007). According to histological and clinical features, human 
melanoma can be classified into four main subtypes. 1) Superficial spreading 
melanoma (SSM), which is the most common type and is located at the 
intraepidermal compartment. 2) Nodular melanoma (NMM), the second most 
common type forms raised nodules and have no radial phase. 3) Lentigo maligna 
melanoma (LMM) is flat in appearance and occurs on sun-exposed skin. 4) Acral 
lentiginous melanoma (ALM) is common on the palms of the hand, the soles of the 
feet and nail bed (Clark et al., 1984; Bandarchi et al., 2010).  
Transformation of a nevus into a melanoma has been hypothesized to be as a result 
of accumulation of genetic alterations, some of which are caused by exposure to UV 
light, this includes mutations in molecules of signaling pathways regulating cell 
survival and proliferation such as Ras/Raf/MEK/ERK and PI3K/AKT (Cohen et al., 
2002; Satyamoorthy et al., 2003). The most common mutation in the 
Ras/Raf/MEK/ERK pathway is a mutation in BRAF, which is found in about 50% of 
melanomas (Davies et al., 2002). The substitution of glutamic acid with valine at 
position 600 (V600E) is the most common BRAF mutation and leads to constitutive 
ERK signaling. RAS is also a target for gain-of-function mutations in melanoma. 
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NRAS, one of the three human Ras genes, is mutated in approximately 30% of 
melanomas with the substitution of glutamine with leucine at position 61 being the 
most common (Davies et al., 2002).  
 
1.1.2 Melanoma invasion 
Upon transformation, tumor progression into the tissue greatly depends on the cross 
talk with neighboring cells and matrix components. During malignant transformation, 
down-regulation of E-cadherin in transformed melanonocytes allows their escape 
from keratinocytes control. Following this event, N-cadherin is up-regulated (Hsu et 
al., 1996) allowing the melanoma cells to switch their communication partners from 
keratinocytes to fibroblasts. In addition to cell-cell communication, soluble factors 
produced by the melanoma cells can induce fibroblasts to secrete growth factors, 
cytokines, matrix proteins, and proteases to generate a tumor-promoting 
microenvironment (Tang et al., 1994; Hsu et al., 2000). Melanoma cells produce 
several factors with stroma-inducing potential, for example basic fibroblast growth 
factor (bFGF) and vascular endothelial growth factor (VEGF) (Mueller and Fusenig 
2004). Stimulated fibroblasts are also a rich source of soluble factors such as stromal 
cell-derived factor 1 (SDF-1) which stimulates tumor cell proliferation (Kalluri and 
Zeisberg 2006). Several cell biological processes are activated in this 
microenvironment, which leads to the growth and progression of melanoma cells into 
the host tissue. The activity of several proteolytic enzymes in the tumor 
microenvironment has been shown to be pivotal in promoting melanoma cell invasion 
by degradation of matrix components or shedding of cellular receptors (Hofmann et 
al., 2000). Several protease families are involved in melanoma invasion, these 
include serine proteases, matrix metalloproeases (MMPs) and more recently also the 
family of A disintegrin and metalloproteases (ADAMs) (Egebald and Werb 2002; 
Mochizuli and Okada 2007).  
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which are 
capable of degrading extracellular matrix proteins, but also process bioactive 
molecules (Visse and Nagase 2003). MMPs produced by tumor or stromal cells 
participate in melanoma progression by degrading basement membrane, remodeling 
the ECM and releasing ECM- and membrane-bound growth factors (McGuire et al., 
2003). These processes in turn influence cell proliferation, migration, invasion, and 
metastasis (reviewed by Zigrino and Mauch 2011). MMPs also affect inflammation 
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and angiogenesis during melanoma progression. For example, the early stage of 
inflammation during melanoma growth is delayed in Mmp-12 knockout mice (Balbin 
et al., 2003). Furthermore, endothelial cells secrete MMPs to degrade blood vessel 
basement membrane and ECM components but also generate endogenous 
angiogenic inhibitors like endostatin from collagen XVIII (Stetler-Stevenson et al., 
1999).   
 
 
Figure 1 Transformation of melanocytes to melanoma. Benign transformation of melanocytes 
leads to formation of melanocytic nevi which progress into dysplastic nevi. The progression 
into a malignant radial or vertical growth melanoma is characterized by the activity of several 
proteolytic enzymes. These proteases contribute to cellular functions leading to malignant 
cell progression through the tissue and intravasation of melanoma cells into blood and lymph 
vessels. (From Zigrino and Mauch, Melanoma Development: Proteases in Melanoma 2011, 
Springer). 
 
Another example of proteolytic enzymes implicated in melanoma progression are the 
serine proteases. The serine proteases plasmin and urokinase plasminogen activator 
(uPA) are involved in cleaving ECM proteins and activate MMPs in the extracellular 
space (Nagase 1997). It is thought that through their role in activating MMP-2 and -
14, serine proteases may play a role in the vertical growth phase transition of 
melanoma (Antonicelli et al., 2007).  In recent years, another group of proteases has 
become interesting in melanoma progression, namely the ADAMs.  
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ADAMs are membrane-bound proteins involved in proteolysis and cell adhesion 
(White 2003). ADAM-9 and -10 were shown to be up-regulated in melanoma while 
ADAM-9 was shown to mediate cellular contact between fibroblasts and melanoma 
cells while ADAM-10 was found to increase melanoma cell migration in vitro (Zigrino 
et al., 2011, Lee et al., 2010). Another member, ADAM-15, was shown to be down-
regulated in melanoma metastasis as compared to primary melanoma (Ungerer et 
al., 2010). The specific role of ADAMs in melanoma however, is presently not yet 
clear.  
 
1.2 ADAM proteases 
1.2.1 ADAM domain structure and function 
The ADAMs are multidomain, type I transmembrane proteins that together with the 
ADAMs containing thrombospondin motifs (ADAMTS), form the adamalysin 
subfamily under the metzincin family of metalloproteases. Members of the ADAM 
family are characterized by a conserved domain structure including, a signal peptide, 
prodomain, metalloprotease, disintegrin, cysteine-rich, epidermal growth factor-like 
domain,  transmembrane domains and a cytoplasmic tail (figure 2) (Seals and 
Courtneidge 2003). ADAMs may exist in two forms, membrane-bound and soluble, 
which derive from alternative splicing.  
The signal peptide at the N-terminus is important in directing ADAM proteins to the 
secretory pathway (Vitale and Denecke 1999). ADAMs may contain a zinc-binding 
motif coordinated by three histidine residues (HExxHxxGxxHD) within their 
metalloproteinase domain. However, only 13 of the circa 22 identified mammalian 
ADAMs contain the catalytic consensus sequence and are thought to be catalytically 
active (Duffy et al., 2011). The prodomain chaperones the proper folding of ADAM 
proteins (Milla et al., 1999) and keeps the metalloprotease site inactive by forming a 
supramolecular complex, the so-called “cysteine-switch”. The “cysteine-switch” is 
formed between a conserved cysteine residue in the prodomain and the active zinc 
ion in the metalloprotease domain. This keeps the protein inactive until the 
prodomain is removed by proprotein convertases or organomercurials, cleaving at a 
conserved Rx(R/K)R site (Roghani et al. 1999; Howard et al. 2000). The removal of 
the prodomain occurs in the trans-Golgi network (Van Wart and Birkedal-Hansen 
1990).   
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Figure 2. Schematic representation of the general domain structure of membrane-bound 
ADAM protein. ADAMs are activated intracellularly by removal of the prodomain. ADAMs 
appear on the cell surface in the activated form anchored to the plasma membrane by the 
transmembrane domain. 
 
ADAMs proteolytic activity has been associated with ectodomain shedding. One of 
the best studied examples of shedding is that of TNF-α originally described by Black 
et al., (1997). Using genetic mouse models Horiuchi et al., (2007) showed that 
shedding of TNF-α in vivo is primarily mediated by ADAM-17. Another example is the 
involvement of ADAM proteases in regulation of notch signaling. ADAM-10 
(kuzbanian, in Drosophila) and ADAM-17 have been implicated in the ectodomain 
shedding of the notch receptor leading to intramembrane proteolysis and release of 
the cytoplasmic stub of the receptor (Pan et al. 1997; Brou et al., 2000). 
Translocation of the intracellular domain into the nucleus results in the activation of 
transcription and regulation of developmental processes (Pan et al. 1997; Brou et al., 
2000). ADAMs have also been implicated in the generation of APPα. The 
accumulation of β-amyloid peptide in the brain leads to the development of 
Alzheimer´s disease (Gandy and Petanceska 2000). β-amyloid peptide is produced 
by processing of amyloid precursor protein (APP) by β- and γ-secretases, but a 
soluble form of APPα is produced by the action of α-secretases such as ADAM-9, -
10 and -17 which opposes the adverse effects of the β-amyloid peptide (Amour et al., 
2000; Slack et al., 2001; Hotoda et al., 2002).  Moreover, ADAMs also cleave 
components of the extracellular matrix as has been shown for ADAM-10 and -15 
cleaving collagen type IV in vitro (Millichip et al. 1998; Martin et al. 2002).  
  Introduction 
     6  
Apart from the proteolytic activity, ADAMs are involved, through their disintegrin-
cysteine domains, in receptor binding and mediate cellular interactions. It is unclear 
which sequence in these domains is responsible for adhesive activity as only ADAM-
15 contains the known integrin-binding sequence RGD (arginine-glycine-aspartic 
acid). However ADAM-15 has been shown to bind to αvβ3 and α5β1 in an RGD-
dependent and independent manner (Nath et al., 1999; Eto et al., 2000). Most of the 
ADAMs were thought to interact with integrins through an aspartic acid-containing 
sequence (ECD; glutamic acid-cysteine-aspartic acid) located in the disintegrin loop. 
Mutation of ECD in ADAM-2 to ECA leads to inhibition of sperm-egg binding (Bigler 
et al. 2000; Zhu et al. 2000). However, resolution of the crystal structure of vascular-
apoptosis-inducing protein-1 (VAP-1), a snake venom homologue of mammalian 
ADAMs, has revealed that the disintegrin loop, which contains the ECD motif, is 
masked and inaccessible for protein binding (Takeda et al., 2006). In this study, the 
high variable region in the cysteine-rich domain was shown to be responsible for 
substrate interaction. The function of the EGF-like domain is not clear but it is thought 
that, together with the cysteine-rich domain, it is involved in protein-protein interaction 
leading to cell fusion (Huovila et al., 1996). This has been shown for ADAM-12 during 
the fusion of myoblasts cells in vitro (Yagami-Hiromasa et al., 1995).  
The cytoplasmic tails of the ADAMs contain proline-rich motifs that can bind to SH3 
domain containing-proteins (Howard et al. 1999; Poghosyan et al., 2001). Several 
ADAMs have potential phosphorylation sites for serine-threonine and/or tyrosine 
kinases. Phosphorylation of the cytoplasmic tail and interaction with cytoplasmic 
proteins may influence cell signaling, control maturation, sub cellular localization and 
metalloprotease activity of ADAMs (Izumi et al., 1998; Roghani et al., 1999).  
 
1.2.2 Regulation of ADAM expression and activity 
Potential regulatory mechanisms at the transcriptional and post-translational levels 
have been discussed for the regulation of ADAMs, however lack of knowledge on 
their promoter regions have limited these studies. For ADAM-17, it was shown that 
under hypoxia, activation of the specificity protein 1 (Sp1) a transcription factor that 
binds to the promoter region of ADAM-17 leads to up-regulation of this protein 
(Szalad et al., 2009). ADAM-8 and -9 are also up-regulated under reduced oxygen 
conditions (Valkovskaya 2008; Guaiquil et al., 2009). However, the mechanism that 
governs this regulation, whether it involves Sp1 or another member of this family is 
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unclear. Sequencing of the proximal promoter regions of Adam-9 has identified three 
putative binding sites for transcriptional regulatory elements, namely sites for human 
muscle-specific Mt, barbiturate-inducible element box and CAS interacting (Cong and 
Jia 2009). Binding of these proteins to the Adam-9 promoter and how they affect its 
expression has not yet been analyzed. ADAMs are also regulated at by extracellular 
stimuli for example; ADAM-9 expression is down-regulated by IL-1α at transcript and 
protein level via a JNK mediated mechanism (Zigrino et al., 2005 and A. Schönefuss, 
doctoral thesis) while ADAM-17 expression is induced by IL-1β and TNF-α (Cesaro 
et al., 2009; Turner et al., 2010). 
Protein trafficking and sub cellular localization also regulate the expression of 
ADAMs. ADAMs are trafficked through the golgi compartment and need to be 
transported to the cell surface where their activity is implemented (Mochizuki and 
Okada 2007). Their cytoplasmic tail regulates the sub cellular localization and 
catalytic activity of ADAMs through binding to other cytoplasmic proteins (Izumi et al., 
1998; Roghani et al., 1999). For example, binding of protein kinase C to ADAM-9 and 
-17 regulates shedding of HB-EGF when stimulated with phorbol esters (Izumi et al., 
1998; Doedens and Black 2000). Intracellular binding of PASCIN3 to the cytoplasmic 
tail of ADAM-12 regulates shedding of HB-EGF. Therefore, it was suggested that 
PACSIN3 is involved in the correct transportation of ADAM-12 to the plasma 
membrane (Mori et al., 2003).  
The activity of ADAMs is also regulated by their prodomain which maintains the 
protein in the latent state (Deuss et al., 2008), or by endogenous inhibitors, e.g. 
TIMPs with relative specificity. TIMP-1 was shown to inhibit ADAM-10 while TIMP-3 
inhibits ADAM-10, -12 and -17. However, not all ADAMs are inhibited by TIMPs, for 
instance ADAM-8 and -9 are not inhibited by any member of the TIMPs (Amour et al., 
2002 Amour et al., 1998 and 2000; Loechel et al., 2000). A number of synthetic 
inhibitors with a broad inhibitory spectrum towards ADAMs and MMPs have been 
described, most of these inhibitors function by binding to the catalytic zinc ion. One of 
the most investigated inhibitors is INCB3619, which inhibits ADAM-8, -9, -10, -17 and 
-33 and blocks the release of EFGR ligands (Fridman et al., 2007). Other synthetic 
inhibitors include hydroxamate-based inhibitors CGS 27023 for ADAM-9 (Roghani et 
al, 1999), GW280264 and GI254023 for ADAM-10 and -17 (Ludwig et al., 2005). 
Hence, the regulation of ADAMs will depend on their expression profile, stimulus, 
inhibitor and possibly substrate specificity as it has been suggested that ADAMs 
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have intrinsic substrate specificity which limits their proteolytic activity (Hattori et al., 
2000).  
 
1.3 ADAM-9 
1.3.1 ADAM-9 molecular chracteristics and function  
Like all other ADAMs, ADAM-9 is characterized by a general conserved domain 
structure (Weskamp et al., 1996). ADAM-9 is ubiquitously expressed and exists in 
two forms; membrane-bound and soluble (figure 3). Two soluble variants of the 
ADAM-9 protein have been described. The first was described by Hotoda et al., 
(2002) which lacks exon 18 thus resulting in a frame shift and an early stop codon 
(figure 3; ADAM-9s L). Consequently, it lacks part of the EGF-like domain, the 
transmembrane domain and the cytoplasmic tail and is released in a soluble form. 
The second variant is generated by insertion of an extra exon, designated exon 12 
that produces an early stop codon resulting in the deletion of part of the cysteine-rich 
domain, the EGF-like domain, the transmembrane and the cytoplasmic domain 
(figure 3; ADAM-9s S) (Mazzocca et al., 2005). The first variant was cloned from A-
172 human glioblastoma cells and was identified in various tissues such as heart, 
liver, kidneys and lungs (Hotoda et al., 2002). The second variant has been 
described in activated hepatic stellate cells (Mazzocca et al., 2005) and in breast 
cancer tissue and cell lines (Fry and Toker 2010). 
 
Insertion of an extra exon with a TGA stop codon
prodomain metalloprotease disintegrin Cyseine-rich EGF-like cytoplasmic
tail
ADAM-9
Full length
ADAM-9s L
Lack of exon 18 results in frameshift and an early stop codon. 
TM
RRRR
ADAM-9s S
 
 Figure 3. Schematic representation of membrane-bound and soluble forms of ADAM-9. The 
two soluble variants of ADAM-9 are shown. The furin cleavage site (RRRR) is indicated by 
the arrow. 
 
ADAM-9 is activated intracellularly in the golgi apparatus by removal of the 
prodomain by a pro-protein convertase such as furin (Roghani et al., 1999), thus it is 
exposed on the cell surface or released in the extracellular environment as active 
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enzyme. Proteolytic activity of ADAM-9 has been shown towards molecules with 
important roles in growth and angiogenesis such as EGF, FGFR2iiib (Hotoda et al., 
2002; Izumi et al. 1998; Peduto et al. 2005), VCAM-1 and EphB4 (Guaiquil et al., 
2009). However, ADAM-9 can also directly cleave ECM proteins such as laminin 111 
(Mazzocca et al., 2005) and fibronectin (Schwettman and Tschesche 2001). More 
recently, ADAM-9 was involved in the shedding of ADAM-10, a mechanism that may 
regulate ADAM-10 levels on the cell membrane (Parkin and Harris 2009).  
Apart from its role as a sheddase, ADAM-9 can mediate binding to integrin receptors. 
Interaction of ADAM-9 has been shown with α6β1 integrin on fibrosarcoma cells 
where it enhances cell migration on laminin-coated plates (Nath et al., 2000). Using 
recombinant disintegrin-cysteine rich domain of ADAM-9, ADAM-9 was shown to 
interact with α3β1 integrins on the surface of keratinocytes (Zigrino et al., 2007). 
Further, on fibroblasts interaction of the disintegrin-cysteine rich domain of ADAM-9 
with β1 integrins led to increased secretion of proteolytic enzymes (Zigrino et al., 
2011). Interestingly, the adhesion of these cells to ADAM-9 was shown to be 
independent of the ECD motif, which is in agreement with lack of exposure of this 
sequence (Takeda et al., 2006; see section 1.2.1). Soluble ADAM-9 has also been 
shown to promote colon carcinoma cell invasion in vitro by binding to α2β1 and α6β4 
integrins (Mazzocca et al., 2005). More recently, the same group has demonstrated 
that when express as membrane-bound or secreted as soluble form, ADAM-9 may 
differentially modulate migration of breast cancer cells (Fry and Toker 2010).  
The cytoplasmic tail of ADAM-9 can bind to endophilin and SH3PX1 (Howard et al., 
1999). Given the potential role of endophilin and SH3PX1 in vesicle sorting (Wang et 
al., 2008), this interaction may play a role in regulating maturation and sub cellular 
localization of ADAM-9. Using yeast two-hybrid analysis, MAD2β was identified as a 
cytoplasmic binding partner for ADAM-9. MAD2β shows 23 % similarity to MAD2, 
which is a component of the spindle assembly checkpoint (Nelson et al., 1999). 
Perhaps these interactions with MAD2β are involved in coordinating ADAM-9 function 
with the cell cycle. In addition, ADAM-9 cytoplasmic tail can also bind to PKCdelta 
and regulates phorbol ester induced shedding of heparin-binding EGF and amyloid 
precursor protein (Izumi et al., 1998; Roghani et al., 1999). The different 
characterized functions of ADAM-9 are summarized in figure 4 below.                  
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Figure 4. Overview of ADAM-9 functions. 1, ectodomain shedding of membrane-bound 
growth factors/cytokines and their receptors lead to release of soluble factors which can act 
in an autocrine or paracrine manner. 2, interaction with integrins can influence 
adhesion/migration and signaling. 3, processing of the ECM may affect signaling through 
integrins and cell migration. 4, localization and activity of ADAM-9 can be influenced by its 
cytoplasmic tail.  
 
As to the control of Adam-9 transcriptional activity, it has been suggested that a 
single nucleotide substitution at -1314 influences the transcriptional activity of ADAM-
9 with a gain/loss binding of three putative transcriptional regulatory elements. These 
include the human muscle-specific Mt, the barbiturate-inducible element box and 
CAS interacting (Cong and Jia 2009). Estrogen is possibly an activator of Adam-9 
promoter activity as the transcriptional activity of Adam-9 is increased in human 
neuroblastoma (SH-SY5Y) and human prostate adenocarcinoma (LNCaP) cell lines 
after treatment with estrogen (Cong and Jia 2009). Estrogen functions as a 
transcription factor by binding to the estrogen response element (ERE), altogether 
eight possible ERE sites have been found in the Adam-9 promoter region (Gruber et 
al., 2004; Cong and Jia 2009).  
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1.3.2 ADAM-9 in cancer 
ADAM-9 is up-regulated in various human cancers such as renal, prostate, breast 
cancer and melanoma (O´Shea et al., 2003; Peduto et al., 2005; Zigrino et al., 2005; 
Fritzsche et al. 2008). ADAM-9 is thought to participate in the escape of 
hepatocellular carcinoma (HCC) cells from NK cell-mediated immunosurveillance by 
shedding major histocompatibility complex (MHC) class I–related chain A (MICA), a 
ligand for NKG2D receptor (Kogha et al., 2010). Treatment of HCC cells with 
Sorafenib, a multikinase inhibitor (Keating and Santoro 2009), reduces MICA 
shedding by down-regulating ADAM-9 (Kogha et al., 2010). In a mouse model for 
prostate cancer, ADAM-9 was shown to be highly expressed in well-differentiated 
carcinomas but not in advanced poorly-differentiated tumors (Peduto et al. 2005). 
Ablation of ADAM-9 in W10 animals, which spontaneously develop prostate tumors, 
resulted in the development of only well-differentiated tumors as compared to wild 
type mice, which develop poorly-differentiated tumors suggesting that ADAM-9 is 
involved in the progression of prostate tumors to advanced grades (Peduto et al., 
2005). Using cell-based assays, the authors identified altered FGF and EFG 
signaling because of reduced FGFR2iiib and EGFR cleavage, as possible molecular 
mechanism for the observed effect. However, no in vivo evidence was provided on 
the alteration of these two signaling pathways. Soluble ADAM-9 has been found in 
increased amounts in the peritumoral stroma of liver metastases (Mazzocca et al., 
2005). Interestingly, the soluble and membrane-bound forms of ADAM-9 have 
opposing roles in the migration of breast cancer cells. The soluble form enhances cell 
migration in a protease-dependent manner, while the membrane-bound form inhibits 
cell migration by altering integrin-mediated signaling (Fry and Toker 2010). In vitro 
primary keratinocytes lacking ADAM-9 show enhanced migration, this is reflected in 
vivo during wound healing (Mauch et al., 2010). Accelerated wound re-
epithelialization is observed in Adam-9-/- animals because of altered shedding of 
collagen type XVII (Mauch et al., 2010). Shed collagen type XVII has been described 
as to have inhibitory effects on cell migration (Franzke et al., 2002). 
In human melanoma, ADAM-9 is highly expressed at the tumor-stroma border where 
it is localized in both tumor and stromal cells (Zigrino et al., 2005). ADAM-9 
expression in melanoma cells was confirmed in vitro. However, no correlation was 
observed between Adam-9 transcript levels and the invasive capacity of the cells 
(Zigrino et al., 2005). One functional activity of ADAM-9 in melanoma cells, which 
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might be important in progression of melanoma, is the mediation of heterotypic cell 
interaction between dermal fibroblasts and melanoma cells (Zigrino et al., 2011). 
Despite these observations, the exact role of ADAM-9 in melanoma growth has not 
been determined.  
 
1.4 Animal models for malignant melanoma 
1.4.1 Mouse models 
The increase incidence of melanoma has led to the need for better understanding of 
the molecular mechanisms involved in the commencement and progression of 
melanoma. Relevant animal models for addressing experimental questions would 
benefit melanoma research.  The studies of melanoma in vivo have employed mouse 
xenograft models and genetically modified animals with spontaneous development of 
melanoma. In the xenograph model, melanoma cells propagated in vitro are grafted 
under the mouse skin and allowed to grow (Overwijk and Restifo 2001). Although 
melanoma does not spontaneously develop in these models, it is efficient in 
evaluating the contribution of specific host proteins in tumor progression. Tumor 
development is followed in a short period of 10 to 14 days, tumor cells with different 
genetic abnormalities or manipulations can be used (Richmond and Su 2008).  
Mouse melanoma models, which spontaneously develop melanoma, have been 
generated to epitomize the histopathology of human melanoma. These models have 
the advantage that distinct genetic alterations leading to the development of 
melanoma in humans can be reproduced (Refaeli et al., 2009). Important differences 
in melanoma development between human and mouse is the localization of the 
melanocytes. In humans, the melanocytes are located in the basal layer of the 
epidermis while in mouse they are confined to the hair follicle in the dermis (Herlyn et 
al., 2000); hence, the histopathologies are not exactly the same (Ha et al., 2005). 
Tormo et al., (2006), have described an interesting murine melanoma model 
HGF/CDK4R24C/R24C. This mice over-express hepatocyte growth factor/scatter 
factor (HGF) and carries a knock-in gene of the mutated cyclin-dependent kinase 4 
(CDK4), a mutation which renders CDK4 insensitive to inhibition by p16/INK4a. This 
mutation has been observed in hereditary and sporadic human melanoma (Chin 
2003). The over-expression of HGF leads to continuous signaling through its receptor 
tyrosine kinase c-Met and subsequent activation of the ras signal transduction 
pathway, which promotes melanomagenesis (Otsuka et al., 1998). These mice 
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develop melanoma spontaneously or upon carcinogen treatment in the epidermo-
dermal junction of the skin. Importantly, these tumors are invasive and metastatic 
(Tormo et al., 2006). Another mouse model of melanoma is the Tg(Grm1)EPv(E) 
mice, that over-express the metabotropic glutamate receptor 1 (mGrm1) in 
melanocytes under control of dopachrome tautomerase promoter (Pollock et al., 
2003). This mouse strain develops melanoma at about 6 months of age with major 
location in the tail (Pollock et al., 2003). Ectopic expression of mGrm1 transforms 
melanocytes and causes malignant melanoma in vivo (Oritz et al., 2007). The 
Tg(Grm1)EPv(E) model may recapitulate human uveal melanoma as activation of 
this pathway has been observed in human uveal melanoma (Van Raamsdonk et al., 
2009). The Tyr::CreER; BRAFCA; Ptenlox/lox mouse melanoma model (Dankort et al., 
2009) initiates the substitution of glutamic acid with valine at position 600, a mutation 
observed in human melanoma leading to constitutive ERK signaling (Davies et al., 
2002). All mice develop melanoma with metastasis to lymph nodes and lungs 
(Dankort et al., 2009).  
 
1.4.2 Medaka model 
Non-mammalian animals like fish also develop melanoma. Fish animal models are 
increasingly being use to study melanoma (Craig et al., 2008). Fish models for 
melanoma were first established in Xiphophorus, followed by transgenic melanoma 
models in zebrafish and medaka (Patton et al., 2011). The medaka melanoma model 
was generated by over-expression of the oncogene, Xiphophorus medaka receptor 
kinase (Xmrk) an orthologue of the mammalian epidermal growth factor receptor 
gene set under the control of the pigment cell-specific promoter, microphthalmia-
associated transcription factor (mitf) (Schartl et al., 2009; Meierjohann et al., 2004). 
Fish homozygous for Xmrk all develop melanoma between 2 to 6 weeks of age, 
which are highly invasive and metastatic (Schartl et al., 2009). Uveal melanoma and 
tumor formation in the red and yellow pigment cells called xanthophoroma and 
erythrophoroma respectively have been described (Schartl et al., 2009). This model 
has many similarities with human melanoma for one thing, Xrmk receptor induces 
signaling pathways, which mediate proliferation, resistance to apoptosis and initiation 
of dedifferentiation, events that are similar to those found downstream of mammalian 
Egfr (Meierjohan and Schartl 2006). Xmrk induces the Ras-Raf-MAPK signaling 
pathway, which mediates cell proliferation and differentiation. PI3-K can also bind to 
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the c-terminal of Xmrk leading to activation of Akt and induction of anti-apoptotic 
signaling. Signal transducer and activator of transcription (STAT5) is also activated 
promoting anti-apoptosis by increasing the expression of Bcl-x. These two pathways 
are well described in human melanoma (Satyamoorthy et al., 2003).  
Apart from these indicated similarities, no data on the expression and putative role of 
molecules such as proteolytic enzymes in this model. Whether tumoral and 
peritumoral proteolysis plays a role for disease progression in this model, as shown 
for human and murine melanoma, needs to be investigated. Technical advantages of 
this model is among others, their easy breeding and large number of offsprings 
produced, thus offering a model with screening possibilities for pharmacological 
analysis of potential inhibitors for therapeutic use. 
 
1.5 Aims of the thesis 
After formation of a primary tumor within the epidermal layer, melanoma cells 
progress into the tissue and metastasize to distant organs. Invasion into the dermal 
compartment and distant organs requires among others, cancer cell adhesion to/and 
degradation of the ECM. In addition to several proteolytic enzymes, ADAM-9 was 
found expressed by tumor and stromal cells in malignant melanoma. This protein can 
exert dual functions. On one hand, it is proteolytically active, and on the other hand, it 
functions as a cell adhesion receptor making it a molecule with pivotal roles in 
melanoma development and metastasis. The main aim of this study was to 
investigate at a molecular level how ADAM-9 produced by the host affects growth 
and metastasis of malignant melanoma. To achieve this well established in vivo 
melanoma cell grafting model was used to analyze melanoma growth in mice lacking 
ADAM-9 in the host. Tumor progression was monitored as a function of time and all 
processes important for tumor progression such as inflammation, tumor-induced 
neoangiogenesis and proliferation were analyzed in detail to investigate whether 
ablation of ADAM-9 had an impact on these processes. In addition, the protein 
modifications in the peritumoral environment in tumors from WT or Adam-9-/- animals 
were further investigated in vivo by proteomics. In vitro co-culture systems using 
fibroblasts isolated from WT and Adam-9-/- animals and murine melanoma cells was 
employed to analyze at a molecular level how the expression of ADAM-9 stromal 
fibroblasts affected melanoma-fibroblasts cellular cross-talk at the tumor-stroma 
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border. A direct role for ADAM-9 in ECM processing was addressed using 
biochemical approach with recombinant ADAM-9, active/inactive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Materials and methods 
     16  
2 Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals were purchased in analytical grade from Roth (Karlsruhe), Sigma-
Aldrich (München), Merck (Darmstadt), GIBCO (Karlsruhe) and Perbio 
(Lausanne/Switzerland). Molecular weight markers for proteins, PageRulerTMPlus 
Prestained Protein ladder and PageRulerTM Unstained Protein ladder were from 
Fermentas (St. Leon-Roth). DNA molecular weight markers, 100 bp DNA ladder and 
1 kb DNA ladder as well as restriction enzymes were from NEB (Frankfurt/Main). 
Human recombinant TIMP-1 and fibronectin were from Calbiochem (Darmstadt) and 
R&D systems (Wiesbaden) respectively. Mouse recombinant TNF-α was from 
Miltenyi (Bergisch Gladbach). Rat tail recombinant collagen type I was from Cell 
Systems (Remagen, Germany). 
 
2.1.2 Cell culture material 
Plastic ware for cell culture was purchased from Greiner (Nürtingen), TPP 
(Trasadingen/Switzerland) and Becton Dickinson (Heidelberg). Cell culture media 
were from Invitrogen (Karlsruhe), Biochrom (Berlin) and PAA (Cölbe). Supplements 
(Penicillin/Streptomycin) were from Biochrom and FCS from PAA. Zeocin and 
geneticin (G418) antibiotics were purchased from Invitrogen and PAA respectively. 
Collagenase was from Cell Systems (Troisdorf) and mitomycin C was from Sigma-
Aldrich. 
 
2.1.3 Bacteria, vectors and plasmids 
For transformation of plasmids, Escherichia coli DH5α (Invitrogen) was used. The 
genotype is: F- Φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ-. The linearized vector pCR 2.1, used for 
subcloning, and the eukaryotic expression vector pcDNA4/TO/myc-His were 
purchased from Invitrogen.   
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2.1.4 Antibodies 
Antibodies Company Application Dilution 
Goat anti-ADAM-9 R&D systems  WB 1:1000 
Rat anti-ADAM-9  R&D systems  IF 1:100 
Rabbit anti-ADAM-10 Abcam, Cambridge, UK IF  
Rabbit anti-ADAM-17 Biodesign, Asbach WB 1;1000 
Rabbit anti-MMP-13  Santa Cruz, Heidelberg IF 1:50 
Rabbit anti-MMP-14  Pineda, Berlin IF 1:100 
Goat anti-TIMP-1 R&D systems  WB/IF/ 
Neutralization 
1:1000/1:100 
1:2000 
Hamster anti-TNF-α 
(clone TN3-19) 
eBioscience Frankfurt Neutralization 1:2000 
Rabbit anti-TNFRI Abcam WB 1:10000 
Rat anti-Ki67 (clone 
Tec 3) 
Dako, Hamburg IF/IHC 1:1000/1:50 
Rabbit anti-Cleaved 
caspase-3 
Cell signaling, Frankfurt IHC 1:200 
Rat anti-CD45 (clone 
IBL-3/16) 
AbD Serotec Düsseldorf IF 1:200 
Mouse anti-decorin 
(clone 115402) 
R&D systems Wiesbaden WB/IF 1:1000/1:100 
Rat anti-F4/80 AbD Serotec  IF 1:100 
Rat anti-Neutrophil AbD Serotec  IF 1:100 
Mouse anti-decorin R&D systems  WB/IF 1:1000/1:100 
Rabbit anti-collagen 
14 
Gift from Prof. M. Koch, 
University of Cologne 
WB/IF 1:1000/1:100 
Rabbit anti-collagen 
type I 
Quartett, Berlin WB 1:1000/1:50 
Rabbit anti-fibronectin Sigma Aldrich WB/IF 1:1000/1:100 
Rat anti-CD31 (clone 
MEC 13.3) 
AbD Serotec  IF 1:1000 
Rabbit-anti-mouse 
HRP  
Dako WB 1:2000 
Rabbit anti-goat HRP Dako WB 1:2000 
Rabbit anti-rat 
biotinylated 
Dako  IHC 1:300 
Donkey anti-goat-
Alexa 594-conjugated 
Invitrogen,  IF 1:1000 
Rabbit anti-rat-Alexa 
488-conjugated 
Invitrogen,  IF 1:1000 
Goat anti-rabbit-Alexa 
594-conjugated and 
488-conjugated 
Invitrogen,  IF 1:1000 
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2.1.5 Buffers 
PBS:   136 mM NaCl; 2.6 mM KCl; 10nM Na2HPO4; 1.5 mM KH2  
                                          PO4; pH 7.4 
TBE:                90 mM Tris; 20 mM Na2EDTA; 90 mM boric acid; pH 8  
PBST:            PBS + Tween 20 0.5 % (v/v) TBE  
DNA lysis buffer:   100 mM Tris/HCl pH 8.5; 5 mM EDTA pH 8.0; 0.2% SDS;  
     200 mM NaCl 
Running buffer:     250 mM Tris base, 0.2 M Glycin, 1 % SDS; pH 8.3 
Anode I buffer:     Tris 0.3 M; 20 % Methanol 
Anode II buffer:     Tris 25 mM; 20 % Methanol 
Cathode buffer:     6- Aminohexan acid 40 mM; 20 % Methanol 
Laemmli reducing buffer:  60 mM Tris-HCl pH 6.8; 2 % SDS; 0.1 % Bromphenol 
    blue; 25 % Glycerol; 14.4 mM 2-Mercaptoethanol 
Equilibration buffer:    50 mM NaH2PO4; 20 mM Tris HCl; 100 mM NaCl; pH 8 
Gradient buffer A:  10 mM imidazole; 50 mM NaH2PO4; 20 mM Tris HCl; 100  
    mM NaCl; pH 8 
Elution buffer:   250 mM imidazole; 50 mM NaH2PO4; 20 mM Tris  HCl; 
    100 mM NaCl; pH 8 
Substrate buffer:   50 mm Tris-HCl, 5 mm CaCl2, pH 8.0 
Citrate buffer:    2 mM citric acid; 2 mM sodium citrate; pH 6 
Cell lysis buffer:   PBS + 20 mM NH4OH; 0.5 % Triton X-100 
RIPA buffer:  150 mM NaCl, 0.5 % DOC; 2 % SDS; 1 % NP40; 50 mM  
   Tris; 1 % protease inhibitor cocktail; pH 7.4 
    
  
2.2 Methods 
2.2.1 Cell biology  
2.2.1.1 Cells and cell culture 
COS-7 kidney fibroblasts from African Green Monkey, SV40 transformed were from 
ATCC (Gluzman 1981). B16F0, mouse melanoma cells were a kind gift from Prof. C. 
Blobel, Cornell University, New York (Fidler 1973), and B16F1 were from ATCC 
(Fidler 1975). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % FCS, 100 U/ml penicillin, 100 µg/ml streptomycin. B16F1-
GFP, B16F1 cells stably expressing GFP (Zigrino et al., 2009) were cultured in 
DMEM supplemented with 10 % fetal calf serum (FCS), 100 U/ml penicillin, and 100 
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µg/ml streptomycin and 800 µg/ml G418. The human melanoma cell lines Skmel28 
(Carey et al., 1976), WM164/4 (Herlyn et al., 1990), BLM (Van Muijen et al., 1991), 
A375 (Giard et al., 1973) and 530 (Van Muijen et al., 1991) were cultured in RPMI 
1640 medium containing 10 % FCS, 1 % non-essential amino acids, 2 % L-
Glutamine, 100 U/ml  penicillin, 100 µg/ml streptomycin. Glioma Gli36 cells (Kashima 
et al., 1995) and malignant transformed HaCaT II-4(rt) cells (SCC) (Boukamp et al., 
1990) were cultured in DMEM supplemented with 10 % FCS, 100 U/ml penicillin and 
100 µg/ml streptomycin. Basal cell carcinoma cells (BCC) (Yen et al., 1996) were 
cultured in DMEM-HAM´S F12 supplemented with 10 % FCS, 100 U/ml penicillin, 
100 µg/ml streptomycin, 0.1 % adenin, 0.01% hydrocortisone, 0.001 % cholera toxin, 
1 % EFG and 1% insulin. All cells were cultured at 37 °C with 5 % CO2 and a 
humidity of 95 %.  
 
2.2.1.2 Isolation of primary fibroblasts 
Primary murine dermal fibroblasts were isolated from the back skin of newborn mice. 
Briefly, newborn mice were euthanized by decapitation, cooled on ice for 1 hour and 
disinfected in betaisodona iodine for 1 minute, rinsed briefly in PBS and then for 1 
minute in 70 % ethanol and finally rinsed in PBS. The skin was incubated overnight 
with 0.2 % trypsin at 4 °C. The epidermis was separated from the dermis, which was 
diced finely before incubating with 400 U/ml collagenase (Worthington) for 2–3 hours 
at 37 °C with gentle agitation. Tissue debris was removed by centrifugation at 1200 
rpm. Cell pellet was resuspended in DMEM containing 400 U/ml collagenase and 
isolated fibroblasts were cultured in DMEM containing 10 % FCS, 2 mM glutamine 
and 100 U/ml penicillin, 100 µg/ml streptomycin. The fibroblasts were used between 
passages 2 and 4 for experiments. 
 
2.2.1.3 Preparation of fibroblast conditioned media, cell monolayer and matrix  
For the preparation of conditioned medium, fibroblasts were seeded at a density of 5 
x 104 cells/cm2 in culture plates and cultured overnight at 37 °C. Cells were washed 
twice with PBS and incubated with serum free DMEM for 24 hours. The medium was 
collected and spun down for 5 minutes at 1200 rpm to eliminate cellular debris. 
Supernatants were used immediately for cell-stimulation experiments or stored at -20 
°C for additional analysis. 
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For the preparation of fibroblast monolayer layer, fibroblasts were seeded at a 
density of 5 x 104 cells/cm2 and cultured for 3 days. Cells were washed with PBS and 
fibroblast layers were treated with 40 µg/ml mitomycin-C, for 2 hours at 37 °C to 
inhibit cell growth. For the preparation of fibroblast-deposited matrix the cells were 
lysed with cell extraction buffer and the cellular debris were removed with a pipette 
(Beacham et al., 2007). The matrix was washed gently with PBS; the integrity of the 
matrix was confirmed by staining with 0.25 % Coomassie Brilliant blue (G250, 
Sigma), 2.5 g Coomassie Brilliant Blue dissolved in methanol 45 %, acetic acid 10 % 
and H2O, for 10 minutes at room temperature, washed with PBS and visualized with 
light microscope and recorded with DISKUS 4.50.1638 software.   
 
2.2.1.4 Bromodeoxyuridine (BrdU) incorporation assay  
To analyze cell proliferation, B16F1 cells were seeded at a density of 1 x 104 
cells/cm2 in a 96-well plate for 24 hours. Cells were washed twice with PBS before 
treating with or without recombinant TIMP-1 (0.5 µg/ml) in serum-free media, or with 
serum free fibroblasts conditioned medium (2.2.1.3). Cell proliferation was measured 
using a BrdU Proliferation assay (Roche, Mannheim) according to the manufacturer’s 
instructions. Briefly, cells were labeled with BrdU (10 µM final concentration per well) 
for 2 hours at 37 °C and fixed with 200 µl of “FixDenat” solution for 30 minutes at 
room temperature. After removing the “FixDenat” solution, 100 µl of anti-
Bromodeoxyuridine-peroxidase conjugated antibody working solution was added for 
90 minutes at room temperature. Plates were washed three times with PBS and 
incubated with substrate solution. The developing reaction was stopped with 25 µl of 
1 M H2SO4 after sufficient color development. Colorimetric detection was analyzed at 
450 nm using Victor3TM 1420 Multilabel counter (Perkin Elmer, Wellesley, MA, USA). 
Measurement of empty wells with substrate solution was used as blank. All 
experiments were performed in triplicate and repeated three times. 
 
2.2.1.5 Apoptosis assay 
B16F1 cells were seeded in 6-well plates at a density of 1 x 104 cells/cm² and 
cultured overnight. Culture medium was removed and cells were washed twice with 
PBS before treating with or without fibroblasts conditioned medium pre-incubated 
with recombinant TNF-α (100 ng/ml), or hamster anti-TNF-α antibody (2 µg/ml), or 
goat anti-TIMP-1 antibody (2 µg/ml), or Embrel (5 µ
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before used in cell culture. Cells were incubated overnight and apoptosis was 
quantified by cell death detection ELISA (Roche) according to the manufacturer’s 
manual. Briefly, cells were lysed for 30 minutes at room temperature and clarified by 
centrifuging at 200 x g for 10 minutes. 20 µl of sample was incubated with a mixture 
of anti-histone-biotin and anti-DNA-peroxidase-conjugated antibody in streptavidin-
coated plates for 2 hours at room temperature with shaking (300 rpm). Unbound 
components were removed by washing. Peroxidase activity retained on the plate was 
determined photometrically with substrate solution at a wavelength of 405 nm 
(reference wavelength 490 nm) using Victor3TM 1420 Multilabel counter (Perkin 
Elmer). Measurement of empty wells with substrate solution was used as blank. All 
experiments were performed in triplicate and repeated three times.  
 
2.2.2 Protein analysis 
2.2.2.1 Preparation of lysates   
Cell lysates were prepared after washing the cells with PBS, by scraping cells directly 
in RIPA buffer containing general protease inhibitors (Sigma Aldrich) and incubating 
overnight at 4 °C. Lysates were centrifuged at 12.000 rpm for 15 minutes. The 
clarified supernatants were transferred to new tubes and protein concentration was 
determined using a commercial protein assay (BCATM Protein assay, Pierce) 
according to the manufacturer’s instructions. Protein concentration was determined 
by using freshly prepared BSA standard curve ranging from 0.1 µg/µl to 10 µg/µl, 
showing extinction at 578 nm for defined protein concentrations. Tumor lysates were 
prepared from 6 cryo-tumor sections, each 50 µm thick, which were homogenized in 
Mixer Mill 300 (Retsch, Hann) at 30 Hz for 1.5 minutes  in 1 % SDS/PBS containing 
general protease inhibitors. The homogenate was centrifuged at 12000 rpm for 15 
minutes at 4 °C. The clarified supernatant was transferred to a new tube and protein 
was quantified as described above.  
Protein precipitation was performed using trichloroacetic acid (TCA). For this 
purpose, 50 µg of protein sample was mixed with 1 % Triton-X 100 and 55 % TCA in 
a 1:2 ratio and incubated on ice for 10 minutes, then centrifuged at 10000 rpm for 10 
minutes at 4 °C. Precipitated proteins were washed with ice-cold acetone and dried 
at 37 °C for 1 minute. Proteins were solubilized in Laemmli buffer, heated at 95 °C for 
5 minutes, spun and resolved by SDS-PAGE. 
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2.2.2.2 SDS-PAGE and immunodetection 
Equal amount of proteins were separated by SDS-PAGE under reducing conditions 
on a 10 % or 15 % polyacrylamide gel, according to the molecular weight of the 
protein to be analyzed, and transferred onto a Hybond-C nitrocellulose membrane 
(GE Healthcare, München) in a semidry transfer system (Sigma-Aldrich, Deisenhof). 
The transfer efficiency was assessed by staining the membrane with Ponceau Red 
staining (0.1 % Ponceau S (w/v) in 5 % acetic acid (v/v); Sigma-Aldrich). The 
membrane was blocked with 5 % milk powder in PBST for 1 hour, and incubated 
overnight at 4 °C with the diluted primary antibody (see section 2.1.4). Membranes 
were washed three times with 0.5 % PBST for 10 minutes and incubated with 
horseradish peroxidase-labeled secondary antibody for 1 hour at room temperature. 
After extensive washing, bound secondary antibodies were detected by ECL system 
(Thermo Scientific, Asbach) and the membranes exposed to X-ray films (Thermo 
Fisher, Karlsruhe). 
Alternatively, after separation by SDS-PAGE, proteins were stained with Coomassie 
Blue by incubating the gels in 0.25 % Coomassie Brilliant blue (G250, Sigma), 2.5 g 
Coomassie Brilliant Blue dissolved in methanol 45 %, acetic acid 10 % and H2O, for 
30 minutes at room temperature, followed by destaining with 7 % acetic acid, 10 % 
ethanol overnight at room temperature. After extensive washing in water, gels were 
incubated for 2 hours in 30 % Methanol, 5 % Glycerin diluted in water and dried 
between cellophane foils (Roth) according to the manufacturer’s manual.  
 
2.2.2.3 Zymographic analysis 
Cell culture conditioned media was prepared as described in 2.2.1.3 and fractionated 
by SDS-PAGE containing 1 mg/ml bovine gelatin (Sigma). After electrophoresis, the 
gels were washed in 2.5 % Triton X-100 for 30 minutes to remove the SDS and 
incubated overnight in substrate buffer at 37 °C. The gels were stained with 0.25 % 
coomassie brilliant blue (G250) dissolved in methanol 45 %, acetic acid 10 % and 
H2O and the bands corresponding to gelatinase activities appeared white against the 
pale blue background. 
 
2.2.2.4 Mouse cytokine antibody array 
Cytokine antibody array analysis (Raybio® Mouse Cytokine Antibody Array, Hölzel 
Diagnostika Cologne) was performed using conditioned medium prepared from 
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fibroblasts or using tumor lysates prepared as described in section 2.2.2.1 but using 
Raybio® lysis buffer, according to the manufacturer’s manual. Briefly, membranes 
were blocked for 30 minutes at room temperature with blocking buffer then incubated 
overnight at 4 °C with 1 ml fibroblasts conditioned media or 250 µg tumor lysate 
diluted in blocking buffer. After five washes, the membranes were incubated with 
biotin-conjugated anti-cytokine diluted 1:200 with blocking buffer overnight at 4 °C. 
Bound antibodies were detected with horseradish peroxidase-conjugated streptavidin 
secondary antibody. Proteins were visualized by chemiluminescence detection 
system. 
 
2.2.2.5 Murine TNF-alpha ELISA 
ELISA analysis of TNF-α content in fibroblasts supernatants and lysates, and tumor 
lysates was performed using mouse TNF-α ELISA Kit (Hölzel Diagnostika) according 
to the manufacturers’ manual. 2 ml of fibroblasts supernatants were concentrated 
using Vivaspin with a PES membrane of molecular weight cutoff of 10000 
(VivaScience, Hannover). 200 µg of fibroblasts lysates and 50 µg of tumor lysates 
were used for this analysis. Measurements were performed in triplicates and 
expressed as pg/ml. 
 
2.2.2.6 Immunohistochemistry and immunofluorescence  
The marker Ki67 is largely used as an indicator of cellular proliferation (Urruticoechea 
et al., 2005). To analyze the expression of Ki67, paraffin embedded tumor sections 
were deparaffinized and hydrated. After antigen retrieval by boiling in citrate buffer 
pH 7, at 600 Watts for 5 minutes, endogenous peroxidase activity was blocked with 
0.3 % H2O2 followed by blocking with Avidin/Biotin blocking kit (SP 2001, Vector 
laboratories). For cleaved caspase-3, cryosections were fixed in 1 % PFA and 
permeabilized for 5 minutes in ice-cold acetic acid/ethanol. Sections were incubated 
with primary antibody (see section 2.1.4) overnight at 4 °C; the secondary antibody 
was added for 1 hour at room temperature. Bound antibodies were detected with 
AEC substrate (Dako). The nuclei were stained with hematoxylin.  
For immunofluorecence, cryosections sections were fixed in ice-cold acetone for 8 
minutes and blocked with 10 % normal goat serum or 10 % BSA for 30 minutes at 
room temperature. Primary antibody (see table 1) diluted in 1 % blocking solution 
was added and incubated overnight at 4 °C in a humidified chamber. Sections were 
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washed three times with PBS + 0.05 % Tween. Bound antibodies were detected by 
incubating for 1 hour at room temperature with donkey anti-goat-Alexa 594 or goat 
anti-rat-Alexa 488-conjugated secondary antibodies diluted 1:1000 in PBS + 0.05 % 
Tween. Nuclei were stained using 4,6-diamidino-2-phenylinodole (DAPI; 1:1000; 
Roche), mounted with immumount (Thermo Scientific) and stored in the dark at 4 °C. 
 
2.2.2.7 Tissue histology 
Hematoxylin and eosin (HE) staining was performed on 6 µm cryosections by 
incubating in hematoxylin (Sigma Aldrich) for 3 minutes and washing three times with 
lukewarm tap water. Slides were destained by dipping shortly in acid alcohol (1 % 
HCl in 70 % ethanol) and stained with Eosin (Sigma Aldrich) for 8 seconds. After 
rinsing, sections were mounted using Entelan (Sigma Aldrich) and covered with a 
glass cover slip. Sections were visualized with Leica Microscope as described in 
section 2.2.2.8. 
 
2.2.2.8 Image analysis of staining 
Fluorescently stained tissue sections were analyzed using Nikon and NIS Element 
AR 2.30 software. For assessment of fluorescence staining, two pictures each per 
intratumoral and peritumoral parts of the tumor were taken at 100x magnification. 
Quantification on each recorded tissue field was performed using ImageJsoftware 
(http://rsb.info.nih.gov/ij). The mean number of positive staining was calculated from 
four 100x magnification fields per section. 
Light microscopy analysis was performed using a Leica with, DISKUS 4.50.1638 
software (Heidelberg). Three pictures were taken per section and used for 
quantification. 
 
2.2.3 Analysis of nucleic acids 
2.2.3.1 RNA isolation  
Total RNA was isolated by direct lysis in RNAzol solution (WAK-Chemie Medical, 
Steinbach). Tissue sections were homogenized using Mixer Mill 300 (Haan) for 1 
minute at 30 Hz while cell lysates were collected by scraping and transferred in a 1.5 
ml eppendorf tube; DNA was sheared using a 5 ml syringe and 22 G needles three 
times. After incubating on ice for 5 minutes, RNA was extracted using Chloroform-
isoamyl alcohol mix (24:1; v/v) and incubated on ice for 5 minutes, centrifuged at 
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12.000 rpm at 4 °C for 15 minutes. The upper colorless phase containing the RNA 
was transferred into a new tube and precipitated by adding 1 volume of 100 % 
Isopropanol and incubating for 30 minutes on dry ice. After centrifugation at 10.000 
rpm for 10 minutes, RNA pellet was washed with 75 % ethanol, air-dried, and 
resuspended in DEPC-treated water. Integrity of RNA was analyzed by 
electrophoresis on a 1 % agarose-TBE gel and concentration determined by 
measuring the optical density at 260 nm (OD260 x 40 µg/ µl).  
 
2.2.3.2 Reverse transcriptase and polymerase chain reaction (RT-PCR) 
cDNA was generated by reverse transcription of 1 µg RNA using Oligo d(T)16 
primers (50 µM; Roche) and MuLV reverse transcriptase (50 U/µl) in the presence of  
RNase Inhibitors (20 U/µl; Perkin Elmer) to preserve RNA integrity. Reverse 
transcription was performed using the following conditions: 21 °C 10 minutes; 42 °C 
20 minutes; 99 °C 5 minutes. 2 µl of the cDNA was used to amplify specific 
transcripts by PCR using REDtaqTM ReadyMixTM PCR Reaction Mix (Sigma Aldrich) 
and 10 µM of forward and reverse primers. PCR reactions were performed within the 
linear range of amplification: denaturation (94 °C, 1 minute), annealing (see table 1, 1 
minute), extension (72 °C, 1 minute), and final extension (72 °C, 1 minute). Primers 
used for mouse (m) and medaka (mk) PCR, cycle numbers and product size are 
listed in table 1 below. Amplified cDNA was subjected to electrophoresis separation 
on a 2 % TBE-agarose gel containing 0.5 mg/ml ethidium bromide. Amplification of 
S26 was used as control. The PCR products were detected using Eagle eye UV 
transillumination (Peqlab, Erlangen). The ratios of specific PCR products to S26 were 
quantified by densitometry using the ImageJsoftware (http://rsb.info.nih.gov/ij). 
 
2.2.3.3 Genomic DNA preparation from mouse tails 
Genomic DNA was isolated from 0.5 cm tail by incubating in 500 µl genomic DNA 
lysis buffer containing 200 µg/ml proteinase K overnight at 55 °C with shaking at 300 
rpm. Hairs and undigested tissue were eliminated by centrifuging at 10000 rpm for 10 
minutes at room temperature. The supernatant was transferred into a new tube 
containing 500 µl Phenol-Chloroform-Isoamylalkohol (Roth; ratio 25:24:1) and 
centrifuged at 12000 rpm for 5 minutes. Genomic DNA was precipitated with 1/20 
volume of 3 M sodium acetate and washed twice with 70% ethanol. Pelletted DNA 
was air dried for 5 minutes and dissolved in 100 µl sterile water at 55 °C for 1 hour. 1 
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µl of dissolved DNA was used for genotyping by PCR Primers used for genotyping 
are listed in table 1 above. 
 
Table 1. Primers 
Gene Accession No. Sequence (5’ – 3’; f, forward; r, 
reverse) 
Tm 
(°C) 
No. of 
cycles 
Product 
size (bp) 
mAdam-9 NM_007404 f GTAAGAGATCTGCTTGAACTG  
r TTGCCTCTCTGCGACTAAG  
48 40 130 
mAdam -10 NM_007399 f GCAACATCTGGGGACAAACT   
r TTGCATATCCCTTCCTTTGC  
60 35 350 
mAdam -17 BC145270 f TTGAGCGATTTTGGGATTTC  
r CATCCTCTGGTGGTCCAGTT  
60 35 341 
mCollagen 
XIV 
BC138345 f TGGTGGAGAGCCTGACCCGG  
r GCATCCCACCTGACGCGCAT  
58 35 418 
mCollagen 
type I 
NM_007743 f CTCCCAGCCTTCACTCAGAC  
r GAGCAGCCATCGACTAGGAC  
56 30 587 
mTimp-1 NM_011593 f CTGGCATCCTCTTGTTGCTA   
r AGGGATCTCCAGGTCCACAA  
60 35 567 
mTnfrI M59378.1 f GGCAGAGGAGCCTAGTTG  
r CACACCCAGGAACAGTCC  
50 30 212 
mDecorin NM_001190451 f TGAGCTTCAACAGCATCACC  
r AAGTCATTTTGCCCAACTGC  
50 30 181 
mFibronectin NM_010233 f TGATCATGCTGCTGGGAC  
r CTCGGTTGTCCTTCTTGCTC  
50 30 197 
GFP L29345 
 
f ACCCCGACCACATGAAGCAGC  
r CGTTGGGGTCTTTGCTCAGGG  
68 38 417 
mS26 NM_013765 f AATGTGCAGCCCATTCGCTG  
r CTTCCGTCCTTACAAAACGGCT  
56 30 326 
mAdam-9 
genotyping 
11502 f ACTTGGAACAGACTGTCCA  
r CGTTCATAGTTCTCAAGAG  
54 30 WT 121 
KO 1000 
NeoPolyA 
cassatte 
 f GCTATGACTGGGCACAACAGA  
r CAAGGTGAGATGACAGGAGAT  
55 30 280 
mk Adam-9 ENSORLT00000
021845 
f GTACAACTGAACGTTCGCG  
r GGATGAGCTGAGCTGAG  
50 30 163 
mk Adam-10 ENSORLT00000
006689 
f TGAACCCAAATACATGC  
r CACAATCCACTCGGCGA  
50 30 221 
mk Adam-12 ENSORLT00000
012319 
f TTATATCTCTCGGAGAC  
r CTTGATCTGAAGGCCTT  
50 30 181 
mk Adam-15 ENSORLT00000
021131 
f CCAAGTACATTGAACTGGTG  
r GTTGAGCGTGTCCGTG  
45 30 215 
mk Adam-17 ENSORLT00000
019188 
f TTCGAGCCAATGCCTCC 
r GGTTCTGTCCGGTCAGAT 
50 30 301 
mk Mmp-2 AB033754.2 f AAGTGTGGAGCGACGTC 
r CATCAGCGTTTCCAAAC  
55 30 243 
mk Mmp-9 AB033755.1 f GAAACAGCCTCGCTGTG 
r CATGATGTCAGCGGTGC 
55 30 220 
mk Mmp-13 ENSORLT00000
018115 
f TCCGAATGTGGGCTTTG 
r CTCCAATACTCTTCATC  
45 30 157 
mk Mmp-14 ENSORLT00000
009177 
f AGAGCCACATCTGAAGC 
r GGTCAAAGTGAGTGTCT 
55 30 238 
mk β-actin ENSORLT00000
017152 
f TGTCATGGTGGGTATGG 
r GGTCATCTTCTCCCTGT  
50 30 235 
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2.2.4 Animal experiment 
2.2.4.1 Ethics and animal care 
Adam-9-/- mice of a 129/SvJ and C57BL/6J mixed genetic background were kindly 
provided by Prof C. Blobel, Hospital for Special Surgery, New York, USA. Animals 
were kept in cages covered with air filters under specific pathogen-free conditions. 
The animal experiments have been approved by the local veterinary authority 
authorization 50.203.2-K 37a, 20/05 and 87-51.04.2010 A356.  
 
exon 2
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exon 2 
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exon 2 
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forward
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primer
PCR product 1000bp
PCR product 121bp
3´
3´
 
Figure 5. Simplified schematics of targeted mutation of Adam-9. Diagram shows the 
positioning of the primers for amplifying Adam-9 exon 2. The positioning of the primers allow 
amplification of a 121 bp fragment in wild type animals and a larger 1000 bp fragment in 
knockout animals after successful insertion of the neo cassette. The 121 bp fragment is 
absent in knockout animals. 
 
2.2.4.2 Melanoma grafting 
The initial experiments were performed by comparing wild type (WT) and Adam9-/- 
littermate offsprings of heterozygous Adam9+/- parents. To increase the number of 
animals for this analysis, Adam9-/- or WT offspring were collected from one pair of 
heterozygous Adam9+/- parents. The resulting WT or Adam9-/- mice were mated with 
one another to generate litters of WT or Adam9-/- mice that were closely related, as 
they were derived from the same heterozygous grandparents. Mice were used at the 
age of 6-8 weeks. Animals were anesthetized with a single intraperitoneal injection of 
0.5 ml 10 % ketamine, 0.25 ml 2 % Xylazine in 4.5 ml 0.9 % NaCl. The fur on the 
right flank of the body was shaved and bepanthen (Roche) applied to the eyes to 
maintain eye moisture and protection against irritants. 1 x 106 B16F0 or B16F1 cells 
or 100 µl melanoma explants from HGF/CDK4R24C/R24C mice, were injected 
intradermally into the flank of the mice, using 1 ml syringes with µl scale and 26G ½ 
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0.45 x 13 mm needles (Neolus). The same volume of cells was plated on culture 
dishes to check their viability after injection. Tumor size was measured using a 
precision caliper (Mitutoyo, Neuss) and tumor volume was calculated by multiplying 
the larger diameter with the smaller diameter and the thickness of the tumor. Animals 
were sacrificed at day 3, 6, 10 and 13 post-injection or as indicated. Tumors were 
removed surgically and half the tumor tissue was immediately embedded in optimal-
cutting-temperature compound (Tissue-TEK, Vogel, Giessen) and directly frozen, the 
other half was fixed in formalin overnight at 4 °C and embedded in paraffin. Sections 
were cut at 8 µm for immunofluorescence and immunohistochemistry (see section 
2.2.2.6).  
To analyze metastasis formation, to increase blood flow to the tail, mice were placed 
under a heat lamp and transferred to a holding device to restrains the mouse while 
allowing access to the tail. 1 x 105 B16F1 cells in 0.1 ml PBS were injected into the 
lateral tail vein. After removing the needle, bleeding was stopped by holding the site 
with gauze before returning the mice to their cages. Organs (lungs, lymph nodes, 
kidneys and heart) of the animals were collected after 21 days, washed in PBS and 
for analysis of metastatic formation. Metastasis was analyzed macroscopically by 
counting the number of macro-metastases on the surface of the different organs.  
 
2.2.5 Production of recombinant soluble ADAM-9 protein 
2.2.5.1 Cloning and site directed mutagenesis  
The plasmid containing the short soluble variant of human ADAM-9 was a gift from 
Dr. A. Toker, Boston University, USA. It was cloned using the BamHI and XhoI 
restriction site in the pcDNA4/TO/myc-His vector in frame with a C-terminal c-myc 
and polyhistidine (6x His) tag (figure 6).                       
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Figure 6. pcDNA4/TO/myc-His expression vector used for eukaryotic expression of 
recombinant soluble ADAM-9. Adam-9 was inserted in the BamHI and XhoI restriction sites 
in frame with the c-myc and His tag (edoc.hu-berlin.de/.../HTML/chapter3.htm). 
 
The cDNA encoding the long soluble variant of ADAM-9 (referred to as ADAM-9s L) 
was amplified from cDNA derived from glioma cell line A-172, where it was first 
detected (Hotoda et al., 2002), using primers listed in table 2. These primers were 
designed to contain in the amplified product a HpaI restriction site at the 5´ end and 
an XhoI restriction site at the 3´ end. The resulting PCR product was inserted into 
pCR 2.1 plasmid vector (figure 7) using the TA cloning® kit (Invitrogen) according 
to the manufacturer’s manual.                                             
 
                              
Figure 7. Features of the pCR 2.1 vector with Single 3´-thymidine (T) overhangs for TA 
Cloning (http://igene.invitrogen.com/products/selector/vectors/navs/Cloning%20System/TA). 
 
  Materials and methods 
     30  
Briefly, the PCR product was ran on a 1 % agarose gel and extracted from the gel 
using Qiagen Gel Extraction® Kit. The eluted DNA fragment was incubated with 5 
U/µl Taq-Polymerase (Fermentas) and 10 µM dNTPs (Roche) at 72 °C for 10 
minutes to generate 3’-A-overhangs necessary for the TA-cloning. DNA was ligated 
using 400 U/ml T4 DNA ligase overnight at 14 °C into a linearized pCR vector with 
3´-T-overhangs flanked by EcoRI restriction sites. Plasmid was amplified by 
transformation into competent DH5α bacteria (Invitrogen) by heat shock and grown in 
LB-Medium containing 100 µg/ml Ampicillin (PAA) at 37 °C overnight with shaking 
(125 rpm).  Plasmids were purified with Qiagen Mini-prep® Kit. Cloning was verified 
by digestion with EcoRI and visualization on 1 % TBE-agarose gel. Plasmids 
containing the long soluble variant of ADAM-9 were cleaved with HpaI and XhoI and 
directionally cloned into pcDNA4 vector containing the soluble short variant of Adam-
9 cleaved with the same enzymes. cDNA identity was further verified by sequencing 
(performed by the sequencing facility of the Center for Molecular Medicine, University 
of Cologne). 
 
Table 2. Primers used for cloning of ADAM-9 soluble long and for site directed 
mutagenesis.  
 Tm °C Primer sequence (5’ – 3’; f, forward; r, reverse) 
Adam-9 for. HpaI 50 f. 5´GTTAACTTTAAATAAAGGAGGAAACTGCC 3´ 
Adam-9 rev. XhoI 50 r. 5´ CTCGAGTTTCCCATGTCCATGACAC 3´ 
Adam-9 
mutagenic  
60 f. 5´ CATTGTTGCTCATGCATTGGGTCATAATC 3´ 
r. 5´ GATTATGACCCAATGCATGAGCAACAATG 3´ 
Underlined are the added restriction sites, highlighted in red are the mutagenic base pairs. 
 
The transformer site directed mutagenesis kit (CloneTech laboratories) was used to 
introduce specific mutations in the zinc binding motif of the metalloprotease domain 
(amino acid substitution E>A) leading to generation of a proteolytic inactive protein 
(Rhoghani 1999). The codons for glutamic acid and alanine in the zinc binding motif 
are indicated below; the amino acid resulting from the point mutation is indicated in 
red. Underlined and highlighted in red is the base pair change that leads to the 
conversion of glutamic acid to alanine,  
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Zinc binding motif H     E     L     G     H
ADAM9 - CATGAATTGGGTCAT
Mut. ADAM9   - CATGCATTGGGTCAT
H     A L     G     H
 
Briefly, plasmid DNA was denatured and mutagenic primers were annealed to the 
DNA template for the synthesis of the mutant DNA strand using T4 DNA polymerase 
(5 U/µl) at 37 °C for 2 hours. The reaction was stopped by heating at 70 °C for 5 
minutes. The parental DNA was linearized by adding 1 µl Nde I and incubating for 1 
hour at 37 °C. The mutated strand was amplified by transforming into E.coli DH5α. 
Primers used are listed in table 2 above. Insertion of the mutation was confirmed by 
DNA sequencing, performed by the sequencing facility of the Center for Molecular 
Medicine, University of Cologne.  
 
2.2.5.2 Production and purification of recombinant soluble ADAM-9 
COS-7 cell were seeded at a density of 1 x 103 cells per cm². At a confluency of 90 % 
cells were transfected with 2 µg of pcDNA4/To/myc-His containing either ADAM-9 
soluble long or the mutated (E>A) form using Lipofectamine 2000 (Invitrogen, 
Karlsruhe). Cells were cultured in DMEM for 24 hours after which they were splitted 
and cultured in the presence 500 µg/ml zeocin (Invitrogen) to select stably 
transfected clones. Serum-free supernatants collected and clarified by centrifugation 
at 1200 rpm for 5 minutes. The presence of ADAM-9 in the supernatant was checked 
by western blot before purified by affinity chromatography. TALON metal affinity 
resins (Clontech) were added to the supernatant at a ratio of 1:100, incubated 
overnight at 4 °C to allow binding of the His tagged protein to the resins. Resins were 
washed twice with gradient buffer A and bound proteins were eluded with 250 mM 
imidazole overnight at 4 °C. Purified proteins were concentrated using the Vivaspin 
10000 MWCO PES (VivaScience) by centrifuging at 1200 rpm until the desired 
volume was achieved; the sample was recovered from the concentrate pocket with a 
pipette. Recombinant proteins were stored at 20 °C. 
 
2.2.5.3 In vitro enzymatic analysis 
Recombinant proteins (0.5 µg/µl) were incubated with active or inactive (E>A 
mutated) recombinant soluble human ADAM-9 protein (0.05 µg/µl) in substrate buffer 
pH 8 overnight at 37°C. The reaction was terminated by boiling with 5 µl Laemmli 
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reducing loading buffer at 95 °C for 5 minutes and analyzed by western blot (section 
2.2.2.2). 
 
2.2.6 Statistical analysis 
Results were expressed as mean values with standard deviations (SD) or standard 
error of mean (SEM) as indicated. Student t-test was used to analyze the statistical 
differences. All in vitro experiments were carried out in triplicates and repeated at 
least three times. All statistical tests were performed using GraphPad Prism™ 
software (GraphPad™, Califonia, USA) and a p value < 0.05 was considered as a 
statistically significant. 
 
  Results 
     33  
3 Results 
3.1 ADAM-9 in melanoma  
3.1.1 ADAM-9 in human melanoma in vivo 
ADAM-9 is over-expressed in a number of human cancers including human 
melanoma where it is expressed at the tumor-stroma border by both tumor and 
stroma cells (Zigrino et al., 2005). Latest studies have shown that the expression of 
this protein on the surface of melanoma and stroma cells mediates melanoma-
fibroblasts cell-cell interaction (Zigrino et al., 2011) however the molecular activities 
mediated by these interactions in tumor cells and in host cells, and their functional 
role in melanoma progression are not yet understood. 
 
3.1.2 Analysis of Adam-9 in murine melanoma grafts 
In order to characterize the expression of ADAM-9 in vivo, we injected B16F1 
melanoma cells intradermally in the flank of wild type (WT) mice of a 129/SvJ and 
C57BL/6J mixed genetic background. After 13 days, tumors were harvested and the 
expression and localization of ADAM-9 was analyzed by immunofluorescence. 
ADAM-9 was detected in tumor cells adjacent to the stroma and in peritumoral 
stromal cells (figure 8), an expression pattern which is similar to that observed in 
human melanoma (see section 3.1.1). 
                    
Figure 8. Expression of ADAM-9 in murine melanoma. A, representative image of 
immunofluorescence detection of ADAM-9 in melanomas from WT mice. The arrow indicates 
ADAM-9 expression at the tumor-stroma border. Dashed lines denote the tumor-stroma 
border. IgG control confirms the specificity of the staining. s, stroma; t, tumor; e, epidermis. 
Scale bar, 200 µm. 
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3.2 Role of host-derived ADAM-9 in growth of B16F1 melanoma in vivo  
3.2.1 ADAM-9 expression in melanoma from Adam-9-/- in comparison to WT 
mice 
To investigate the role of host-derived ADAM-9 in melanoma progression in vivo, we 
used mice with complete deletion of Adam-9. These mice do not show any major 
phenotype during development and in adulthood (Weskamp et al., 2002).  
Furthermore, skin formation and differentiation was not altered in the absence of 
Adam-9 (Mauch et al., 2010). Disruption of Adam-9 in these animals was confirmed 
by genotyping of tail genomic DNA, by amplification of a fragment of the NeoPolyA 
cassette sequence used to disrupt the Adam-9 gene (Weskamp et al., 2002) and a 
fragment of the Adam-9 exon2 (figure 9A). The Adam-9 exaon2 primers were 
positioned so that a 121bp fragment is amplified in WT animals and a larger 1000bp 
fragment in knockout animals after successful insertion of the neo cassette. The 
121bp fragment is absent from knockout animals (figure 5; section 2.2.4.1). 
Transcript and protein expression of ADAM-9 in melanoma from Adam-9-/- mice in 
comparison to those from WT mice was analyzed. Adam-9 transcripts were analyzed 
by PCR and protein expression by immnunofluorescence. Adam-9 transcript was 
detected in healthy back skin from WT mice but absent in the skin from Adam-9-/- 
animals, thus confirming host depletion (figure 9B). In melanomas from Adam-9-/- 
animals (induced as described for WT mice, section 3.1.2 above), Adam-9 transcript 
was detected in reduced amounts compared to melanomas from WT mice. These 
data were confirmed by quantitative PCR analysis (figure 9B lower panel). In 
melanoma developed in Adam-9-/- mice, ADAM-9 protein was absent the surrounding 
stroma and expressed, to a lesser extent, in the tumor mass compared to tumors 
from WT mice.  
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Figure 9. Expression of Adam-9 in Adam-9-/- and WT mice. A, genotype of Adam-9-/- and WT 
mice. Lack of Adam-9 is shown by the presence of a band for NeoPolyA cassette and 
absence of a band for Adam-9 exon2. Water was used as negative control. B, upper panel,  
Adam-9 transcripts in back skin of mice and melanoma from WT and Adam-9-/- mice. S26 
ensures equal loading. Lower panel, relative expression levels of Adam-9 transcript as 
analyzed by quantitative real time PCR. Data are represented as the relative average 
expression (n=3). ∗∗ p< 0.0028. C, ADAM-9 protein expression in melanoma from Adam-9-/- 
and WT mice. The arrow indicates ADAM-9 expression at the tumor-stroma border. Dashed 
lines denote the tumor-stroma border. IgG control confirms the specificity of the staining. s, 
stroma; t, tumor. Scale bar, 200 µm.  
 
3.2.2 B16F1 tumor growth kinetics 
Melanoma tumor growth kinetic in mice was determined by grafting B16F1 murine 
melanoma cells, stably expressing GFP, into the flank of age and sex-matched litters 
of WT and Adam-9-/- animals. Tumor growth was measured with a precision caliper, 
over a period of 13 days. Tumors developed in WT mice had an average volume of 
0.017 cm³ at day 3 and 0.56 cm³ at day 13 (figure 10). In Adam-9-/- mice, we observe 
significantly larger tumors with an average size of 0.036 cm³ at day 3 post injection 
and 2.1 cm² at day 13, a 3-fold increase in tumor size as compared to WT animals. 
Furthermore, at day 13 post injection, 10 out of 12 knockout mice had tumors larger 
than 1 cm³ while only 3 out of 14 WT mice developed tumors larger than 1 cm³.  
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Figure 10. Loss of host-derived ADAM-9 favors B16F1 melanoma growth. B16F1 melanoma 
growth upon intradermal injection of B16F1 melanoma cells in the flank of Adam-9-/- and WT 
mice. Tumor volume was measured using a precision caliper and average size is presented 
as mean ± SEM (day 3: WT n=27, Adam-9-/- n=26; day 6: WT n=22, Adam-9-/- n=20; day 8 
and 10: WT n=18, Adam-9-/- n=16; day 13 WT n=14, Adam-9-/- n=12). ∗∗∗ p< 0.0001.  
 
Gauiquil et al, (2009) reported reduced tumor growth in Adam-9-/- mice after 
subcutaneous injection of B16F0 cells. To exclude the possibility that increased 
tumor growth observed in Adam-9-/- animals was specific to the melanoma cell type, 
we performed similar experiments using a less aggressive melanoma cell line, the 
subline B16F0 (Fidler 1975). Moreover, to demonstrate that this finding is also true 
for primary tumor cells we used explants from spontaneously developed melanomas 
prepared from HGF/CDK4R24C/R24C mice (Tormo et al., 2006). To exclude the 
possibility that different amounts of Adam-9 produced by these melanoma cells could 
influence tumor growth, we analyzed Adam-9 expression in these cells by RT-PCR. 
This analysis showed comparable amounts of Adam-9 transcript in B16F0 and 
B16F1 cell lines as well as explants from HGF/CDK4R24C/R24C mice (figure 11C) thus 
excluding altered ADAM-9 expression profile as causative for any differences 
observe in tumor growth. 
When grafted intradermally in mice, a similar difference in tumor growth was 
observed in all the different melanoma cells, with tumors developed in Adam-9-/- mice 
larger than those from WT animals (figure 11A and B). This indicates that the 
difference in tumor growth between WT and Adam-9-/- is not specific to the 
melanoma cell type used but rather depending on the host.  
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Figure 11. Melanoma development is increased in Adam-9-/- mice. B16F0 cells and tumor 
explants from HGF/CDK4R24C/R24C mice were injected intradermally into the flanks of WT and 
Adam-9-/- mice and  tumor volume of (A) B16F0 cells (WT and Adam-9-/- n=6) and (B) 
melanoma explants from HGF/CDK4R24C/R24C mice (WT and Adam-9-/- n=5) was measured as 
a function of time. All values are expressed as mean ± SEM.  C, RT-PCR analysis of Adam-9 
mRNA expression in cells used in in vivo tumor growth experiments. 
 
3.2.3 Melanoma metastasis in Adam-9-/- mice 
In mice, as in human melanoma development is followed by progressing of tumor 
cells into the underlying dermis and metastasis to distant organs. Melanoma 
metastasis to the lungs is often the first site of visceral metastasis (Balch et al., 
2003). The regional lymph nodes are the first lymph nodes to encounter fluid draining 
from the primary tumor and are thought to represent the first site tumor cells will 
spread to (Nathanson 2003). To investigate whether ablation of ADAM-9 in the 
stroma leads to altered metastasis formation, B16F1 colonization of lymph nodes and 
lungs was characterized by amplification of GFP transcripts, expressed by B16F1 
cells, using total RNA prepared from these different organs. Although tumors were 
larger in Adam-9-/- as compared to WT mice, the number of lungs and lymph nodes 
harboring GFP-positive tumor cells was similar in Adam-9-/- and WT animals at day 3, 
6, and 10. At day 13, there was a 10 % decrease in metastasis to lungs and lymph 
nodes in Adam-9-/- mice compared to WT (figure 12A).  
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Figure 12. Loss of Adam-9-/- does not affect metastasis. A, RT- PCR amplification of the GFP 
to detect B16F1 melanoma cells in lungs and lymph nodes. Results are expressed as a ratio 
of the number of positive animals to the total number of animals analyzed. B, upper panel, 
representative pictures of the analyzed organs. Scale bar 5 mm. Lower panel, analysis of 
metastasis to different organs after B16F1 injection into the tail vein. Visible metastasis on 
the surface of organs was identified macroscopically and counted presented as number of 
positive organs. 
 
In considering the steps required for successful metastasis, extravasation of 
circulating tumor cells from blood vessels into target organs is a critical process. The 
metastatic potential of blood-borne tumor cells was evaluated by tail vein injection. 
B16F1 cells were injected intravenously into 8 weeks old female WT and Adam-9-/- 
mice. After 21 days, the animals were sacrificed and metastases formation in the 
lymph nodes and visceral organs analyzed visually to assess the number of macro-
metastasis. Metastases appeared on the surface of the organs as dark spots (figure 
12B), while metastasis to lymph nodes was detected by increased size of the lymph 
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node as well as the presence of strongly pigmented melanoma cells. There was no 
difference in the number of macro-metastasis on the surface of lungs from WT and 
Adam-9-/- animals (figure 12B, upper panel). No metastasis was observed in lymph 
nodes and hearts from WT and Adam-9-/- animals. Only one kidney from Adam-9-/- 
and none from WT mice had macro-metastasis. This suggests that while host-
derived ADAM-9 may play a role in melanoma growth, but is not involved in 
modulating metastasis. 
 
3.3 Processes involved in melanoma growth 
3.3.1 Vascularization of tumors 
Ablation of host-derived Adam-9 favors melanoma development, several events may 
contribute to this effect, including, angiogenesis, inflammation and stroma activation. 
Angiogenesis is important to supply nutrients to the tumor and in addition offers a 
way to metastatic spread (Bergers and Benjamin 2003). ADAM-9 is expressed on 
endothelial cells and has been shown to influence pathological neovascularization in 
the retina after oxygen restriction, probably by processing membrane-bound proteins 
present on endothelial cells (Guaiquil et al., 2009). We investigated whether 
alterations in angiogenesis contributed to the increase tumor growth in Adam-9-/- 
animals, and analyzed blood vessel density by immunodetection of the endothelial 
cell marker CD31 (De Young et al., 1993). This analysis was performed using 
sections from four different animals per group, per time point. ImageJ software 
analysis was used to quantify the amount of positive CD31 pixel count from four 100x 
magnification fields per section. We observed increased blood vessel density within 
the tumor (intratumoral) in Adam-9-/- as compared to WT tumors at all three time 
points (figure 13A and B) but no differences in peritumoral vascularization (figure 13A 
and B).  
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Figure 13. Intratumoral angiogenesis is increased in Adam-9-/- mice. A, tumor vascularization 
was analyzed by staining for CD31 in 3, 6 and 10 days old tumors from WT or Adam-9-/- 
mice. Dashed lines indicate the tumor-stroma border. e, epidermis; s, stroma; t, tumor. Scale 
bar 100 µm. B, quantification of CD31 staining by densitometry on four 10x fields. Graph 
shows the average positive staining (count) per 10x field. WT n= 4; Adam-9-/- n=4, per time 
point. Scale bar 100 µm. ∗ p<0.05, ∗∗p<0.005. 
 
The increased blood vessel density observed in tumors from Adam-9-/- mice could be 
associated to the increased tumor size in these animals and not to the absence of 
ADAM-9. Hence, we have analyzed blood vessel density in tumors of comparable 
sizes even though from different time points. We could not observe differences in 
blood vessel density in the peritumoral and intratumoral area when tumors of similar 
sizes from WT and Adam-9-/- animals were analyzed (figure 14). This indicates that 
the previously observed difference in blood vessel density (figure 13) was due to the 
increased tumor size in Adam-9-/- mice and not to increase neoangiogenesis in the 
absence of Adam-9.  
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Figure 14. Loss of ADAM-9 does not influence angiogenesis. Quantification of blood vessel 
density in tumors of similar sizes, but from different time points, from WT and Adam-9-/- mice. 
Blood vessel was quantified by densitometry on four 10x fields per section. Graph shows the 
average blood vessel count per 10x field. WT n= 5, Adam-9-/- n= 5. s, stroma; t, tumor. Scale 
bar 100 µM. 
 
3.3.2 Inflammatory response in tumors 
Another event important for tumor development and modulating tumor growth is 
inflammation (reviewed by Coussens and Werb 2002). Tumor cells produce a variety 
of cytokines and chemokines, which attract inflammatory cells such as macrophages, 
lymphocytes and neutrophils, to the tumor site. This infiltrate in turn generates an 
environment that can promote or suppress tumor growth. Whether altered 
inflammation contributed to the increased tumor growth we have observed in the 
absence of ADAM-9 (3.1.2), was determined by analyzing the recruitment of 
inflammatory cells to the tumor site. This was achieved by immunofluorescent 
detection of neutrophils, T-/B-cells (CD45) and macrophages (F4/80) (figure 15A). To 
semi-quantify the number of infiltrated cells, the staining was quantified by 
densitometry. No difference was observed in the staining intensity of all analyzed 
cells at day 3 and day 6. At day 10 no difference was observed in the amount of pixel 
count of neutrophils and B-cells recruited to the tumor site, however, a slight but not 
significant increase in macrophage infiltration was observed in tumors from Adam-9-/- 
mice (p=0.089, figure 15B). These results suggest that altered inflammation did not 
contribute to the increase in tumor growth observed in knockout animals.  
  Results 
     42  
 
Figure 15. Inflammatory reaction at the tumor site is not altered. A, analysis of inflammation 
in tumor sections by staining for T-/B-cells, neutrophil and macrophages (CD68) markers all 
shown in green. DAPI was used to stain the nuclei. e, epidermis; s, stroma; t, tumor. Scale 
bar, 100µM. B, quantification of T-/B-cells, neutrophils and macrophages by densitometry of 
four 10x fields per section. Data represents mean ± SD (Adam-9-/- n=10, WT n=9). 
 
3.3.3 Proliferation and apoptosis of B16F1 melanoma cells in vivo 
Unlimited potential to replicate and resistance to apoptosis are hallmarks of cancer 
and a balance between these two contributes to tumor development (Hanahan and 
Weinberg 2000). We studied the proliferation of B16F1 melanoma cells in vivo by 
staining for Ki67, a nuclear proliferation marker (Urruticoechea et al., 2005) by 
immunohistochemistry in melanoma sections from WT or Adam-9-/- animals. Positive 
cells were counted in three representative fields and expressed as a percentage of 
the total cells in the same field. Tumor cell proliferation was significantly increased in 
tumors from Adam-9-/- mice (40.3 % positive cells) as compared to those from WT 
mice (15.8 % positive cells, figure 16A). We have analyzed apoptosis by 
immunochemical detection of active cleaved caspase-3, a key executor of apoptosis 
(Lakhani et al., 2006). The number of cleaved caspase-3 positive cells was 2.6 fold 
lower in tumors from Adam-9-/- mice as compared to WT, being 1.2 % in Adam-9-/- 
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and 3.2 % in WT mice (figure 16). Altered ratio of Ki67 and active cleaved caspase-3 
was also observed in tumors from WT and Adam-9-/- animals of similar sizes despite 
the difference in excision time (figure 16B), demonstrating the differences in 
proliferation and apoptosis were due to the lack of ADAM-9. These results suggest 
that increased tumor growth in Adam-9-/- animals resulted from altered balance 
between proliferation and apoptosis.  
 
         
 Figure 16. Tumor cell proliferation is increased in Adam-9-/- animals while apoptosis is 
reduced. A, tumor cell proliferation as determined by detection of Ki67. The number of Ki67 
positive cells in three 20x fields were counted and expressed as a percentage of the total 
number of cells. Assessment of tumor cell apoptosis by detection of cleaved caspase-3 
followed by quantification as described above. (WT n=6; Adam-9-/- n=7). B, analysis of 
proliferation and apoptosis in tumors of similar sizes as described above. (n=5 per genotype). 
Values are expressed as mean ± SEM. Scale bar 200 µM. ∗ p<0.05; ∗∗ p<0.005. 
                            
3.4 Role of fibroblast-derived Adam-9 on melanoma cell growth 
3.4.1 Influence of cellular contacts and matrix synthesis/modification on 
melanoma cell proliferation  
There is increasing evidence that cancer-associated fibroblasts play a role in the 
progression of cancer by direct cell-cell communication with tumor cells or, indirectly 
by secreting cytokines and growth factors and matrix components (Orimo et al., 
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2001; Mueller and Fusenig 2004). To gain more insights on the molecular 
mechanisms how the lack of Adam-9 in the host and in particular in stromal 
fibroblasts can influence B16F1 cell proliferation and apoptosis, we used in vitro co-
culture systems of B16F1 cells and primary dermal fibroblasts isolated from WT or 
Adam-9-/- newborn mice.  First, we ask the question whether in the absence of 
ADAM-9, cellular contacts between melanoma cells and fibroblasts alter melanoma 
cell proliferation. For this, we cultured B16F1 cells on a dense monolayer of 
mitotically inactive fibroblasts (figure 17 upper panel, experimental setup). After 24 
hours, B16F1 cell proliferation was measured by BrdU incorporation, to detect cells 
that were actively replicating their DNA. Mitotic inactivation of fibroblast was 
performed to ensure that only the proliferation of B16F1 cells are measured and to 
annul the effect of cytokine/growth factors which are produced during cell 
proliferation. The absorbance was measured at 450 nm and expressed as a 
percentage to the positive control (B16F1 cell proliferation in the presence of 10 % 
FCS). The absorbance of mitotic inactive fibroblast monolayer was also measured to 
correct for background absorbance. Induction of proliferation was detected in B16F1 
cells upon direct culture with fibroblasts monolayers, however, no difference was 
detected between B16F1 cells cultured on WT or Adam-9-/- fibroblasts monolayer 
(figure 17).         
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Figure 17. Cell-cell interactions do not influence B16F1 cell proliferation. Assessment of 
B16F1 cell proliferation by BrdU incorporation after 24 hours incubation on WT or Adam-9-/- 
mitotically inactivated fibroblasts monolayer. The experimental set-up is shown in the upper 
panel, Cell proliferation was calculated as percentage relative to the 100 % FCS control (+, 
10 % FCS; -, serum free control). The background absorbance of the mitotically inactive 
fibroblast monolayer was also measured. Shown is a representative of three independent 
experiments. Values are presented as mean ± SD. 
 
Next we wanted to find out whether the extracellular matrix, its proteolytic 
modification or synthesis, also played a role in the induction of melanoma cell 
proliferation (Lukashev and Werb 1998) since ADAM-9 has been identified as a 
matrix modifying enzyme (Schwettmann and Tschesche 2001; Mazzocca et al., 
2005). To investigate whether lack of ADAM-9 leads to altered matrix modifications 
and in turn affect B16F1 cell proliferation, we have plated B16F1 cells on matrices 
produced by either WT or Adam-9-/- fibroblast as described by Beacham et al., (2007) 
see section 2.2.1.3.  
 
     
Figure 18. Matrix synthesis/modifications do not influence B16F1 proliferation. Cell 
proliferation of B16F1 cells after 24 hours incubation on matrix derived from WT or Adam-9-/- 
fibroblast. Experimental set-up and coomassie blue staining of matrix deposited by WT and 
Adam-9-/- fibroblasts is depicted in the upper panel. Lower panel, B16F1 cell proliferation 
after 24 hours culture on matrix-coated plates in serum-free conditions was assessed by 
BrdU incorporation. Cell proliferation in the presence of 10% FCS was used as the 100 % 
reference value (+, 10 % FCS; - serum free). Background absorbance of cell matrix was also 
measured. A representative of three experiments is shown. 
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Matrix deposition was confirmed by light microscopy visualization after staining with 
Coomassie brilliant blue (figure 18, upper panel). Matrix deposited by WT fibroblasts 
was evenly distributed while matrix deposited by Adam-9-/- fibroblasts appeared 
dense and seemed to consist of larger fibers (figure 18, upper panel). Proliferation of 
B16F1 cells grown on these matrices in serum-free conditions was assessed by 
BrdU incorporation; matrix background absorbance was also measured to correct for 
background absorbance. After 24 hours, B16F1 cells cultured on matrix deposited by 
WT or Adam-9-/- fibroblasts were not stimulated to proliferate (figure 18).  
These data indicate that the absence of ADAM-9 in fibroblasts does not result in 
altered cellular contacts or matrix modification involved in the modulation of B16F1 
cell proliferation ADAM-9.   
 
3.4.2 Soluble factors as mediators of melanoma-stoma communication 
leading to cell proliferation  
One of the best described activities of ADAM proteases is their proteolytic cleavage 
of growth factors and cytokines leading to autocrine or paracrine cell signaling. One 
important example is the activation of EGF family proteins (Blobel 2005). Thus, 
ADAMs can play an important role in modulating cellular cross talk by cleaving cell 
surface proteins. To address whether altered release or synthesis of soluble factors 
in the absence of ADAM-9 influenced B16F1 cell proliferation, B16F1 cell 
proliferation was assessed either in indirect co-cultures with fibroblasts. In one case 
fibroblasts were seeded in transwell culture systems were they were separated from 
the melanoma cells by a membrane with 0.4 µm pore size permitting permeation of 
soluble molecules. In another case co-culture was performed by culturing the B16F1 
cells in the presence of serum-free conditioned medium (c.m.) prepared from sub 
confluent WT or Adam-9-/- fibroblasts (see scheme in Figure 19). B16F1 cell 
proliferation was assessed by BrdU incorporation. Cell proliferation was expressed 
as percentage relative to the proliferation of cells in the presence of 10 % FCS, which 
was set as the 100 % reference value. B16F1 cells co-cultured with Adam-9-/- 
fibroblasts in transwell chambers grew significantly faster, by approximately 19 %, 
compared to those co-cultured with WT fibroblasts (figure 19). Similarly, increased 
B16F1 proliferation was detected when cells were cultured with media conditioned 
from Adam-9-/- as compared to those cultured with media from WT dermal fibroblasts 
(p=0.037; figure 19). These data show that the increased melanoma cell proliferation 
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was mediated by soluble factors produced by Adam-9-/- fibroblasts and indicates that 
an active cross talk between the two cell types was not necessary.  
 
Figure 19. B16F1 cell proliferation is induced by supernatant from Adam-9-/- fibroblasts in 
vitro. Upper panel, schematic presentation of experimental setup. B16F1 cell proliferation by 
BrdU incorporation after 24 hours incubation in transwell with WT or Adam-9-/- fibroblasts or 
with conditioned media (c.m) from Adam-9-/- or WT fibroblasts. The mean absorbance of 
triplicates was expressed as a percentage to the 100 % reference value (+, 10 % FCS; -, 
serum free). Mean values are presented and the bar represents the standard deviation. One 
representative experiment out of three is shown. * p<0.05. 
 
The proliferative potential of conditioned medium from Adam-9-/- fibroblast was not 
limited to B16F1 melanoma cells only. Different cancer cell lines were incubated for 
24 hours in serum-free medium (-) as negative control or in 10 % FCS as positive 
control (+) or in the presence of conditioned media collected from WT or Adam-9-/- 
fibroblasts. Cell proliferation was assessed by BrdU incorporation. As shown in figure 
20, conditioned media from Adam-9-/- but not WT fibroblasts, could significantly 
increase the proliferation of the human melanoma cell line A375 or the glioma cell 
line Gli36. A minor but not significant increase was detected by culturing basal cell 
carcinoma cell line (BCC) and malignant transformed HaCaT cell line II4RT (SCC) 
cells with c.m. from Adam-9-/- as compared to WT conditioned media (figure 20). This 
shows that the pro-proliferative effect of conditioned media from Adam-9-/- fibroblast 
was not limited to murine melanoma cells (B16F1) but was also detected with human 
melanoma and glioma cells, whereas the proliferation of epithelial tumor cells was 
not affected.   
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Figure 20. Adam-9-/- fibroblasts conditioned medium (c.m.) enhances the proliferation of 
melanoma cell lines. Cells were cultured in the absence (-) or presence (+) of serum or with 
WT or Adam-9-/- fibroblasts c.m. for 24 hour. Cell proliferation was assessed by BrdU 
incorporation. Proliferation in the presence of 10 % FCS was set as the 100 % reference 
value. Values are expressed as mean ± SD. p-values were calculated for cells cultured with 
c.m. from Adam-9-/- fibroblasts as compared to cells cultured with c.m. from WT fibroblasts. ∗ 
p<0.05 
 
As shown in 3.3.3, in vivo, in parallel to increased proliferation we could also detect 
reduced apoptosis in the absence of host ADAM-9. To find out whether soluble 
factors, which mediated increased proliferation, also influence cell apoptosis we 
analyzed apoptosis of B16F1 cells after treatment with c.m. from WT or Adam-9-/- 
fibroblasts. Stimulation of B16F1 cells with recombinant TNF-α was used as positive 
control, as it effectively induce apoptosis in B16F1 cells, and set as the 100 % 
reference value. Apoptosis was measured by ELISA detection of the amount of 
cytoplasmic oligonucleosomes released into the cytoplasm during apoptosis. The 
apoptosis of B16F1 cells after culture with Adam-9-/- fibroblasts conditioned media 
was significantly reduced compared to cells treated with WT conditioned media 
(figure 21). This indicates that the reduction in apoptosis observed in tumors from 
Adam-9-/- mice was also mediated by a soluble factor-derived mechanism. 
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Figure 21. Apoptosis of B16F1 cells. B16F1 cell apoptosis analyzed by ELISA detection of 
cytoplasmic oligonucleosome and expressed as percentage relative to the 100 % reference 
value (cell apoptosis in the presence of 100ng/ml TNF-α ). The graph is a representative of 
three independent experiments. Values represent mean ± SD. ∗ p<0.05. 
 
3.5 The role of soluble factors in the regulation of melanoma cell proliferation 
3.5.1 Identification of soluble factors in Adam-9-/- fibroblasts 
To gain insight on factors, which were altered in Adam-9-/- fibroblasts and in turn 
could modulate B16F1 melanoma cell proliferation and apoptosis, we analyzed 
growth factor/cytokine levels in fibroblasts supernatants by RayBio® mouse cytokine 
antibody array. This antibody-based array can simultaneously detect 62 different 
mouse cytokines and growth factors. This analysis was also performed with tumor 
lysates from day 3 tumors, the time point at which tumor size starts to differ between 
WT and Adam-9-/- mice. The densities of the different cytokines dots were quantified 
by densitometry using imageJ software, the background intensity (blank) was 
subtracted, and the data was normalized to the biotin-conjugated IgG positive 
internal control. The Adam-9-/- to WT expression ratio was calculated and we set a 
minimum a fold change of two as baseline above which expression was considered 
significant. Several factors were identified which were up-regulated in lysates from 
tumors developed in the Adam-9-/- animals as compared to WT, however we have 
only considered those factors which were equally altered in both, tumor lysates and 
fibroblasts supernatants (figure 22). This indicated which factors in vivo might be 
derived mainly from differential secretion by stromal fibroblasts than other cell types 
around the tumors. Factors up-regulated in Adam-9-/- fibroblast supernatants as 
compared to WT, were amongst others, TIMP-1 (6.72 fold), TNF-α (5.58 fold), 
sTNFRI (3.66 fold) and sTNFRII (3.53 fold). These proteins were also up-regulated in 
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tumor lysates from Adam-9-/- compared to WT mice; TIMP-1 (7.92 fold), TNF-α (3.17 
fold), sTNFRI (31.99 fold) and sTNFRII (17.05 fold). Presented in figure 22 are the 
relative expression levels of the soluble factors analyzed and their fold difference in 
Adam-9-/- as compared to WT fibroblast supernatants or tumor lysates. There is a 
small group of factors differentially expressed in Adam-9-/- fibroblasts or tumor lysates 
that are known to play an important role in tumor cell proliferation and apoptosis.  
Fibroblast supernatantTumor lysate
2.1412.6427.001.6331.8852.12SDF-1α
0.733.442.531.3235.0846.30GM-CSF
3.172.056.501.7919.3334.68IL-6
17.050.9416.033.5311.1939.46sTNFRII
31.931.6552.783.6615.4856.65sTNFRI
3.181.324.195.584.7026.21TNF-α
0.713.612.561.2041.3749.71BLC
7.913.6128.596.722.8819.35TIMP-1
2.5612.3031.471.6362.51101.66MIP-2
2.027.5915.350.97108.81105.78IL-1a
ratio Adam-9-/- vs. WT WT Adam-9-/-ratio Adam-9-/- vs. WTWT Adam-9-/-
 
Figure 22. Differential expression of soluble factors. Relative expression levels of 
cytokines/growth factors as quantified by densitometry, values are expressed as arbitrary 
units/ biotin-conjugated IgG positive control. Presented are some differentially expressed 
proteins detected in both fibroblast supernatants and tumor lysates in Adam-9-/- as compared 
to WT.   
 
3.5.2 TIMP-1 expression in fibroblasts and melanoma cells 
Tissue inhibitor of metalloproteinases-1 (TIMP-1), among others, was identified from 
RayBio analysis as being up-regulated in Adam-9-/- fibroblasts supernatants and 
tumor lysates as compared to WT controls (3.3.1). To confirm the results obtained 
from the RayBio array, TIMP-1 protein expression was analyzed in the supernatants 
of five different WT and Adam-9-/- fibroblast preparations by immunoblot analysis. 
The volume of supernatant used was normalized to the protein content in fibroblast 
lysate (50 µg). TIMP-1 was highly up-regulated in all Adam-9-/- fibroblast 
supernatants as compared to WT, two representatives are shown for each genotype 
in Figure 23A.  
Regulation of TIMP-1 expression may occur at transcript and protein levels (Richard 
et al., 1993; Aicher et al., 2003). Semi-quantitative analysis of TIMP-1 transcripts in 
all five different fibroblast preparations, displayed a significant increase in Adam-9-/- 
as compared to WT fibroblasts (figure 23B). Thus, the increased secretion of TIMP-1 
derives from de novo synthesis. In vivo, by immunofluorescence analysis of 
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melanoma tumor sections, TIMP-1 was detected mainly in the stoma and in a few 
tumor cells and tumor penetrating stromal cells at the tumor periphery. TIMP-1 
expression was increased in peritumoral areas of melanomas developed in Adam-9-/- 
animals with strong positivity detected in many fibroblast-like cells, whereas little 
expression was observed in the peritumoral stoma of melanomas developed in WT 
littermates (figure 23C). 
 
       
Figure 23. TIMP-1 expression is increased in the absence of ADAM-9. A, analysis of TIMP-1 
expression in supernatants from Adam-9-/- and WT dermal fibroblasts by western blot. Shown 
is a representative of n=5 per genotype. Ponceau staining ensures equal loading of gels. B, 
amplification of Timp-1 transcript by RT-PCR on cDNA synthesized from RNA isolated from 
fibroblasts. Shown is a representative per group n=8. RT-PCR was quantified by 
densitometry, and shown as mean expression relative to S26 ± SD. C, detection of TIMP-1 
(red) in acetone fixed tumor sections from WT or Adam-9-/- mice. DAPI was used to stain the 
nuclei. IgG control confirms the specificity of the staining. Dashed lines indicate tumor-stoma 
border.  s, stoma; t, tumor. Scale bar 200 µM.  
 
3.5.3 Effect of TIMP-1 on melanoma cell proliferation 
TIMP-1 is generally known as the natural inhibitor of several matrix metalloproteases 
however, it may also function as a growth and/or survival factor in a MMP-
independent manner (Moller Sorensen et al., 2008; Ricca et al., 2009). To assess the 
growth stimulating effect of TIMP-1 on B16F1 melanoma cells, we analyzed B16F1 
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cell proliferation in the presence of exogenous TIMP-1. Cell proliferation was 
expressed as percentage relative to cell proliferation in the presence of 10 % serum 
(+). Cells cultured in the presence of 0.5 µg/ml recombinant TIMP-1 grew 4 times 
faster than cell grown in serum-free medium (-) (figure 24) and their growth was 
comparable to that observed in the presence of 10 % serum. Serum also contains, 
among other cell proliferating factors, also TIMP-1 ranging from 0.1 to 0.46 µg/ml 
depending on the distributor (Hayakawa et al., 1992). Showing that TIMP-1 is used 
as a growth factor in serum.   
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Figure 24. Exogenous TIMP-1 enhances B16F1 cell proliferation. B16F1 cell proliferation in 
the presence of recombinant TIMP-1 (r. TIMP-1) was assessed by BrdU incorporation 
compared to serum-free control. (+, 10 % serum positive, -, serum-free). The graph is a 
representative of three experiments. Values are expressed as mean ± SD.  ∗∗ p<0.0008. 
 
To investigate whether TIMP-1 exerts a growth stimulating effect in human 
melanoma cells (as shown in figure 24), we cultured different melanoma cell lines 
with two concentrations of recombinant TIMP-1 (0.5 and 1 µg/ml) for 24 hours and 
assessed cell proliferation. As control, cells were cultured in serum-free medium or 
medium containing 10 % FCS (100 %). The proliferation of all cell types was 
significantly increased when cells were cultured in medium containing recombinant 
TIMP-1, except the cell line A375 that showed only a modest increase in cell 
proliferation (figure 25). This indicates that TIMP-1 can act as a growth-stimulating 
factor for both murine and human melanoma cells. 
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Figure 25. TIMP-1 dependent proliferation of human melanoma cell lines. Cells were cultured 
in the absence or presence of 0.5 µg/ml or 1 µg/ml recombinant TIMP-1 for 24 hour. Cell 
proliferation was assessed by BrdU incorporation. Proliferation in the presence of 10 % FCS 
was set as the 100 % reference value. The graph is a representative of three experiments 
showing mean ± SD. p-values were calculated for TIMP-1 treated cells compared to serum-
free controls ∗ p<0.05, ∗∗ p<0.0065, ∗∗∗ p<0.0002. 
 
To prove that the enhanced amount of TIMP-1 in Adam-9-/- fibroblast supernatants is 
responsible for the increase in B16F1 cell proliferation we neutralized TIMP-1 using 
specific antibody prior to melanoma cell stimulation with Adam-9-/- fibroblasts 
supernatant. As control, mouse IgG was used at the same concentration as the 
TIMP-1 antibody. Neutralization of TIMP-1 in fibroblasts media resulted in a 
significant reduction in B16F1 cell proliferation by approximately 30 %  reaching  
levels comparable to those detected when  B16F1 were cultured in the presence of 
WT fibroblast conditioned medium (figure 26A). TIMP-1 has also been shown to 
mediate survival of erythroid UT-7 (Lambert et al., 2003) and human breast epithelial 
cells (Li et al., 1999). We therefore investigated whether TIMP-1 apart from 
proliferation, may also influence B16F1 cell-survival. Neutralization of TIMP-1 did not 
affect B16F1 cell apoptosis, as no differences in cytoplasmic oligonucleosome was 
detected in cells cultured in the presence of Adam-9-/- fibroblasts conditioned media 
with or without TIMP-1 neutralization (figure 26B). The IgG control had no effect on 
B16F1 cell proliferation and apoptosis (figure 26A and B). These results indicated 
that the increased TIMP-1 in Adam-9-/- fibroblasts conditioned medium contributes to 
the enhanced B16F1 cell proliferation in vitro but does not affect apoptosis.  
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Figure 26. Neutralization of TIMP-1 reduces B16F1 cell proliferation but does not affect 
apoptosis. A, analysis of B16F1 cell proliferation in the presence of fibroblast conditioned 
medium (c.m.) with or without anti-TIMP-1 antibody (a-TIMP-1; 2 µg/ml) or control IgG (2 
µg/ml).  Cell proliferation in the presence of 10 % serum (+) was used as positive control. B, 
apoptosis of B16F1 cells after neutralization of TIMP-1 in Adam-9-/- fibroblasts (c.m.) with an 
anti-TIMP-1 antibody (2 µg/ml). Mouse IgG (2 µg/ml) was used to show specificity. Cell 
apoptosis in the presence of recombinant TNF-α (TNF-α; 100 ng/ml) was used as the 100 % 
reference value. Each graph is a representative of three independent experiments. Values 
represent mean ± SD. ∗ p<0.05,  ∗∗ p<0.005. 
 
3.5.4 Expression of TNF-α and TNFRI   
TNF is one of the most potent inducer of apoptosis. Its function is mediated by 
binding and activation of TNFRI death domain, which initiate the apoptotic cascade 
(Rath and Aggarwal 1999). TNF-α and TNFRI exist as transmembrane proteins, 
which undergo ectodomain shedding by the activity of ADAM proteases, releasing 
soluble forms (Garton et al., 2006). An additional soluble form has been described for 
TNFRI; the exosome associated 55 kDa (Hawari et al., 2003).  
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RayBio mouse cytokine analysis identified TNF-α and its soluble receptors (TNFRI 
and II) as up-regulated in supernatants from Adam-9-/- fibroblasts and in tumor 
lysates from Adam-9-/- compared to WT mice (figure 22). To investigate whether 
alterations in the TNF/TNFR axis mediate reduced apoptosis detected in melanoma 
grown in Adam-9-/- mice, we first confirmed the results obtained from the RayBio 
array. The TNF-α protein levels were analyzed by ELISA in WT and Adam-9-/- 
fibroblast lysates and supernatants. The concentrations of TNF-α in cell lysates and 
supernatants were increased in Adam-9-/- as compared to WT fibroblasts. Similarly, 
also in tumor lysates of melanomas induced in Adam-9-/- mice TNF-α concentration 
was 3-fold higher than in those from WT animals (figure 27A).  
TNFRI protein expression was analyzed by western blot in fibroblast supernatants 
and cell lysates. This analysis revealed that apart from the exosome associated 55 
kDa soluble protein of TNFRI, the 28 kDa shed soluble form was detected in Adam-9-
/-
 but not in WT fibroblast supernatants (Figure 27B). This increased shed TNFRI in 
Adam-9-/- fibroblast supernatants was accompanied by a concomitant decrease of 
the membrane bound form detected in lysates from Adam-9-/- as compared to WT 
fibroblasts (figure 27B). TNFRI transcript analysis showed no differences between 
WT and knock out fibroblasts (figure 27C). 
 
Figure 27. TNF-α and sTNFRI expression is increased in Adam-9-/- fibroblasts. A, ELISA 
detection of soluble and membrane bound TNF-α in fibroblast culture supernatants and 
cellular lysate and, in melanoma tissue lysate obtained from WT or Adam-9-/- mice (n=4 per 
genotype). Values are presented as mean ± SD. B, representative images of TNFRI protein 
and transcripts in Adam-9-/- and WT fibroblast by western blot (n=4 per genotype) and RT-
PCR (n=8 per genotype). Ponceau staining was used to control equal loading of 
supernatants while actin was used as loading control for protein lysates. S26 was used as 
control of cDNA loading. 
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3.5.5 Modulation of apoptosis induced by TNF-α and TNFRI 
As described above, the majority of TNF-α´s biological activity is mediated through 
binding to TNFRI (Chen and Goeddel 2002) and can be inhibited by the proteolytic 
release of the receptor, which functions as a decoy receptor (Garton et al., 2006). We 
hypothesize that increased sTNFRI in the supernatant from Adam-9-/- fibroblasts 
neutralize TNF-α, leading to reduced cellular apoptosis. To prove this theory, B16F1 
cells were cultured first with c.m. from Adam-9-/- fibroblasts supplemented with 100 
ng/ml recombinant murine TNF-α, a concentration that would not only saturate the 
soluble TNFRI but also be available for binding to membrane-bound receptor. Under 
these conditions, B16F1 cells underwent apoptosis to levels similar to that of cells 
stimulated with supernatants from WT fibroblasts (figure 28). On the other hand, 
neutralization of TNF-α in WT fibroblast supernatant with neutralizing TNF-α antibody 
or Enbrel (also known as Etanercept), a recombinant fusion protein which functions 
as a decoy receptor, prior to B16F1 cell stimulation, significantly reduced B16F1 
apoptosis by 25 % and 35 % respectively. Pre-incubating WT fibroblast supernatant 
with IgG control did not affect B16F1 apoptosis (figure 28).  
  
Figure 28. Neutralization of TNF-α reduced B16F1 apoptosis. Apoptosis was measured in 
B16F1 cells by ELISA detection of cytoplasmic oligonucleotides. B16F1 cells were cultured 
with supernatants from fibroblasts pre-incubated with or without recombinant TNF-α (r. TNF-
α, 100 ng/ml), anti-TNF-α antibody (a-TNF-α, 2 µg/ml), Enbrel (5 µg/ml) or IgG control (2 
µg/ml). B16F1 cell apoptosis in the presence of recombinant TNF-α was used as 100 % 
reference value. Data represents mean ± SD. ∗ p<0.0353, ∗∗ p<0.0065, ∗∗∗ p<0.0009. 
 
The proteolytic release of the soluble TNFRI was shown to be mediated primarily by 
ADAM-10 and -17 (Zheng et al., 2004). Expression of Adam-10 and -17 transcripts in 
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Adam-9-/- fibroblasts was indeed higher than in WT cells as detected by RT-PCR 
analysis (figure 29A). Quantification of the amplified transcripts by densitometry and 
normalization to S26 control showed that Adam-10 and -17 were significantly up-
regulated in Adam-9-/- as compared to WT fibroblasts (figure 29A, right panel). At the 
protein level, total protein of ADAM-10 and -17 proteins were up-regulated in Adam-
9-/- fibroblasts as compared to WT, however a tiny band corresponding to active 
ADAM-10 was observed only in WT fibroblasts while more active ADAM-17 was 
observed in Adam-9-/- cells (figure 29B). The second ADAM-17 band in Adam-9-/- 
fibroblasts is likely an unspecific band. 
 
 
Figure 29.  Adam-10 and -17 are up-regulated in the absence of Adam-9. A, analysis of 
Adam-9, -10 and -17 transcripts in Adam-9-/- and WT fibroblasts by RT-PCR (n=5). S26 was 
used as internal control and H2O as negative control. RT-PCR was quantified by 
densitometry, normalized to S26 control and expressed as the mean ± SD.  Shown is a 
representative PCR for each genotype. ∗ p < 0.05. ∗∗ p < 0.005. B, ADAM-10 and -17 protein 
expression in fibroblasts. Actin serves as loading control. Shown is a representative of n=4 
for each genotype. 
 
ADAM-10 but not ADAM-17 is inhibited by TIMP-1, which is up-regulated in Adam-9-/- 
fibroblasts (Amour et al., 2000). We therefore hypothesize that increased shedding of 
TNFRI is the result of increased ADAM-17 synthesis. To inhibit the shedding of 
TNFRI by ADAM-17, Adam-9-/- fibroblasts were incubated overnight with a 
hydroxamate-based inhibitor, TNF-α Protease Inhibitor-0 (TAPI-0) whose target 
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includes ADAM-17, MMP-1 (not expressed in mouse, Balbin et al., 2000) and MMP-2 
(Roghani et al., 1999). As control, fibroblasts were incubated with DMSO, which was 
used as solvent for the inhibitor. The generation of soluble TNFRI was analyzed by 
western blot. Treatment with TAPI-0 effectively reduced shedding of TNFRI in Adam-
9-/- fibroblasts as less shed TNFRI was detected in supernatant of fibroblasts treated 
with TAPI-0 (figure 30). In addition to the decreased shed form of TNFR1 we also 
detected reduced exosome associated receptor. In parallel, the membrane-bound 
form of TNFRI was increased in lysates from fibroblasts treated with TAPI-0 as 
compared to control (figure 30). Stimulation of B16F1 cells with supernatants from 
TAPI-0 treated fibroblasts resulted to a 20 % increase in apoptosis as compared to 
control (figure 30). Taken together, these results support the hypothesis that reduced 
B16F1 cell apoptosis results from neutralization of TNF-α by soluble TNFRI, which is 
increased in Adam-9-/- fibroblast supernatants. 
 
               
Figure 30. Inhibition of TNFRI shedding reduced B16F1 apoptosis. Left, western blot analysis 
of TNFRI in Adam-9-/- fibroblasts with or without TAPI-0 (10 µM) treatment. Ponceau and 
actin were used as loading control for supernatant and lysates respectively. Right, analysis of 
B16F1 cell apoptosis after culturing with supernatant from Adam-9-/- fibroblasts treated with 
or without TAPI-0. B16F1 cell apoptosis induced with recombinant TNF-α was used as 100% 
reference value. Data represents mean ± SD. ∗∗∗ p<0.0009. 
 
3.5.6 Differential fibroblast gene expression in the absence of Adam-9 
To identify possible factors that could give insight as to how Adam-9 may alter protein 
expression in fibroblasts, RNA isolated from WT and Adam-9-/- fibroblasts were analyzed 
by RNA array. This analysis was performed in cooperation with Prof. Jay Fox of the 
University of Virginia, USA. The data was analyzed with Ingenuity Systems IPA. 
Identification of statistically significant changes was performed by t-test. Of the genes 
analyzed, 64 were up-regulated while 116 genes were down-regulated in Adam-9-/- 
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fibroblasts compared to WT fibroblasts. We have considered as significant only genes 
regulated with p-values less than 0.05 or a fold change of at least 2 (positive values, up-
regulated; negative values, down-regulated). The identified genes included those involved 
in transcriptional regulation, cell proliferation, melanoma progression, and synthesis of 
extracellular matrix protein. The differentially regulated genes are presented in table 3 
below. 
 
Table 3.  Differential fibroblasts gene expression after Adam-9 knockout 
 
7.8Col14a1
3.7Cdca8 
7.5Slc1a3
-2.9IGFBP4
-3.7Tcfec
7.1E2f7
-2.8Atf4
2.0Col1a1ECM
-2.8Cdkn2a
3.4Runx3
-2.6Tcf15
Fn1
Cdkn2a
Dlk1 
Kif23 
Klf14 (Sp6)
Regulated genes
-3.7
-2.8
8.3
5.3
2.6
Fold change Adam-9-/- vs. WT
Transcription factors
Proliferation of cell lines 
Melanoma progression
Functional annotation
 
 
Among the genes differentially regulated in fibroblast the absence of ADAM-9, were 
genes involved in proliferation, strongly increased for instance was Delta like 1 
homolog (drosophila) (Dlk1). Interestingly, Dll-1 (Delta-like 1, in mammals) has been 
shown to be a substrate for ADAM-9 when ADAM-12 is absent (Dyczynska et al., 
2007) and its cleavage, as shown for the notch receptor, may lead to modulation of 
intracellular signaling (Qi et al., 1999). Transcription factors were also differentially 
regulated like trans-activating protein (Sp6 or Klfl4) and E2F transcription factor 
(E2f7) which were both up-regulated in the absence of Adam-9. We have also 
detected genes involved in the regulation of cell cycle like cyclin dependent kinase 
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inhibitor 2A (Cdkn2a) which was down-regulated, and cell division cycle associated 8 
(Cdca8) that was up-regulated in the absence of Adam-9. Genes involved in the 
synthesis of extracellular matrix components for example fibronectin (Fn1) and 
collagen type XIV (Col14a1) were also differentially expressed. The differential 
expression of transcription factors and membrane receptors among others which 
could offer the molecular link between ADAM-9 and regulation of intracellular 
signaling could not be evaluated within the time-frame of this thesis and remain to be 
validated.  
 
3.6 ADAM-9 and its role in the modification of the peritumoral matrix   
3.6.1 Extracellular matrix protein expression at the tumor-stoma border 
The tumor microenvironment consist of the extracellular matrix (ECM) and stromal 
cells (Mueller and Fusenig 2004). ADAM-9 has been shown to cleave extracellular 
matrix proteins including fibronectin (Fn1) and laminin 111 (Schwettmann and 
Tschesche 2000; Mazzocca et al., 2005). To analyze how ablation of ADAM-9 in vivo 
influences matrix composition around the tumors we performed proteomic analysis of 
the tumor-stoma border of day 3 tumors from WT and Adam-9-/- animals. This 
analysis was done in cooperation with Prof. Jay Fox at the University of Virginia. The 
black dotted lines in figure 31 indicate the tumor-stoma border area that was 
microdissected and analyzed by mass spectrometry. We have identified differentially 
expressed proteins belonging to different molecular functional groups amongst others 
binding, catalytic activity and enzyme regulator activity.  
 
       
Figure 31. Analysis of ECM proteins at the tumor-stoma border in melanoma from WT and 
Adam-9-/- mice.,Black dotted lines indicate the areas that was extracted and analyzed by 
mass spectrometry, WT n=2; Adam-9-/- n=2).  t, tumor; s, stoma; e, epidermis; m, 
subcutaneous muscle. Scale bar 50 µM.  
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The relative expression of the proteins analyzed were used to calculate the fold 
change of proteins in Adam-9-/- as compared to WT. 496 proteins analyzed were 
similarly expressed in both genotypes. Only 53 proteins were altered at the tumor-
stoma border of tumors from Adam-9-/- animals compared to WT controls. Proteins 
with a fold change of at least two were considered relevant (positive values, up-
regulated; negative value, down-regulated). The fold changes of differentially 
expressed proteins are presented in table 4 below, where positive values indicate up-
regulation and negative values indicate down-regulation at the tumor-stoma border in 
tumors from Adam-9-/- mice as compared to those from WT controls.  
 
Table 4. Differential expression of proteins at the tumor-stoma border. 
-8,16272 kDaFatty acid synthase
-2,6778 kDaLong-chain-fatty-acid--CoA ligase 1
4,3932 kDatriosephosphate isomerase 1
2,2062 kDaPyruvate kinase isozymes R/L 
2,2069 kDa
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit 2 
-2,7326 kDatrypsin 4
-2,7227 kDaMast cell protease 4
2,2022 kDaPeroxiredoxin-1
2,2031 kDaPeroxiredoxin-4
Enzymes
2,0040 kDaDecorin
-4,00272 kDaFibronectin
-4,00193 kDaIsoform 1 of Collagen alpha-1(XIV) chain
2,00184 kDaCollagen alpha-1(V) chain
2,00145 kDaCollagen alpha-2(V) chain
-2,00139 kDaCollagen alpha-1(III) chain
2,00130 kDaCollagen alpha-2(I) chain
2,00138 kDaIsoform 1 of Collagen alpha-1(I) chain
Fold change Adam-9-/- vs. WT tumorMWECM proteins
 
 
Of the differentially expressed ECM proteins, decorin, collagen type I and V were up-
regulated in Adam-9-/- animals. Fibronectin, collagen type III and XIV were down-
regulated at the tumor-stoma border of melanomas developed in Adam-9-/- animals 
compared to WT animals. Enzymes involved in the fatty acid metabolism such as 
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fatty acid synthase and Long-chain-fatty-acid-CoA ligase 1 were down-regulated in 
tumor-stoma border of tumors from Adam-9-/-. Enzymes involved in glycolysis such 
as triosephosphate isomerase 1 and pyruvate kinase isozymes R/L, and enzyme 
involved in protein gylcosylation, dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 2, were up-regulated. The antioxidant enzymes 
Peroxiredoxin-1 and 4 were up-regulated regulated in tumor-stoma border of tumors 
from Adam-9-/-. Surprisingly no matrix remodeling enzymes were detected; reasons 
for this could be the extraction and analysis procedure that do not enables analysis of 
low expressed proteins (personal communication with Prof J.W. Fox). 
The differential expression decorin and collagen XIV, which are important in collagen 
fibrillogenesis (Lozza 1998; Ansorge et al., 2009), collagen type I, which has a 
predominantly structural role in tissue (Kadler et al., 2007) and fibronectin which 
mediates a variety of cellular interactions with the ECM (Ansorge et al., 2009) were 
further analyzed by immunofluorescence. Collagen type I was analyzed by picrosirius 
red staining. Increased intensity of staining for decorin was observed at the tumor-
stoma border in tumors from Adam-9-/-, whereas fibronectin expression was not 
altered at the tumor-stoma border however, increased positivity was detected in the 
periphery of the tumor (figure 32A). No obvious differences were detected in the 
expression of collagen XIV at the tumor-stoma border in tumors from both animals 
(figure 32A). Collagen type I bundles visible by polarized light visualization of 
picrosirius red stained tissue (figure 32B right panel), were moderately increased at 
the tumor-stoma border in melanomas from Adam-9-/- animals as compared to those 
from in WT animals (figure 32B). Thus, increased expression of collagen type I and 
decorin could be confirmed, whereas reduction in fibronectin and collagen XIV at the 
tumor-stoma border, as suggested by the proteomic analysis, could not be confirmed 
by this analysis. 
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Figure 32. Expression of ECM proteins in melanoma from WT and Adam-9-/- mice. A, 
analysis of decorin, fibronectin and collagen type XIV (green), nuclei (blue) by 
immunofluorescence. For negative control, sections were incubated in 1 % blocking buffer 
without primary antibody. B, analysis of collagen type I by immunohistochemistry using 
picrosirius red with bright field pictures on the left (collagen type I, red; nuclei, brown-grey) 
and polarized light assessment on the right (collagen type I, red). Shown are representative 
images (WT n= 5; Adam-9-/- n=5). t, tumor, s, stoma. Scale bar 400µM. 
 
3.6.2 Expression of ECM proteins by fibroblasts 
We have detected in the tumor-stoma border of melanomas from Adam-9-/- and WT 
mice differential expression of matrix proteins. In the tumor microenvironment, 
fibroblasts are largely responsible for the synthesis of ECM components (Rodemann 
and Muller 1991). To find out whether the altered expression of ECM proteins in vivo 
was due to altered secretion by fibroblasts in the absence of ADAM-9, we have 
examined the synthesis of the differentially expressed ECM proteins by Adam-9-/- and 
WT fibroblast in vitro. By immunoblotting we detected slightly increased amounts of 
decorin in Adam-9-/- fibroblasts lysates. A low molecular weight form of decorin of 
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about 30 KDa, known to be a cleaved form (Monfort et al., 2006), was detected in 
increased amounts in Adam-9-/- compared to WT fibroblasts supernatant (Sp.) (figure 
33). Fibronectin and collagen type XIV were detected in both lysates and 
supernatants from WT and Adam-9-/- fibroblasts in comparable amounts (figure 33). 
Collagen type I was increased in Adam-9-/- as compared to WT fibroblast lysates and 
supernatants. A low molecular weight fragment of about 70 KDa was detected in WT 
as well as Adam-9-/- fibroblast supernatants. However, the amount of this fragment 
was reduced in Adam-9-/- fibroblasts compared to WT (figure 33).  
 
Figure 33. ECM protein expression by fibroblasts supernatant and lysate. Synthesis of ECM 
proteins by dermal fibroblasts as analyzed by western blot. Ponceau was used to control 
loading and transfer efficiency of fibroblast supernatants while actin was used as loading 
control for protein lysates. Images are representatives of WT n=5, Adam-9-/- n=5. 
 
Tumor cells can influence the composition of the tumor stoma by producing cytokines 
that regulate the activity of fibroblasts, including the secretion of ECM components 
(De Wever and Mareel 2003). To mimic the in vivo situation of how tumor cells 
influence the secretion of ECM proteins by fibroblasts, WT and Adam-9-/- fibroblasts 
were cultured with conditioned media from B16F1 melanoma cells. Analysis of 
protein expression by western blot showed a minimal increase in decorin expression 
by Adam-9-/- as compared to WT fibroblast lysates and supernatants (Sp.) (figure 34). 
While the expression of fibronectin and collagen type XIV were not altered by 
treatment with B16F1 conditioned media, a prominent increased in collagen type I 
was detected in Adam-9-/- as compared to WT fibroblasts lysates and supernatants 
(figure 33 and 34). The low molecular weight fragment of collagen type I of about 70 
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KDa (previously described in figure 33) was also detected in reduced amounts in 
Adam-9-/- as compared to WT fibroblast supernatants (figure 34). This indicates that 
the increased collagen type I, observed in the tumor-stoma border of tumors from 
Adam-9-/- animals (figure 32) may derive from fibroblast. Decorin, fibronectin, 
collagen XIV and collagen type I were not detected in the B16F1 supernatant used in 
treating the fibroblasts.  
 
 
Figure 34. Influence of B16F1 on ECM protein secretion by fibroblasts. Expression of ECM 
proteins, decorin, fibronectin, collagen XIV and collagen type I by fibroblasts in the presence 
of supernatant from B16F1 cells using western blot analysis. Ponceau and actin were used 
as loading control for supernatant and lysate respectively. Shown are representatives of WT 
n=5, Adam-9-/- n=5. 
 
To find out whether the minor difference in expression of decorin and the more 
prominent difference in collagen type I in Adam-9-/- fibroblast were because of 
increased de novo synthesis, we analyzed the transcript expression of these proteins 
in WT and Adam-9-/- fibroblasts using semi-quantitative RT-PCR. The expression of 
decorin was significantly increased in Adam-9-/- fibroblast with a p-value of 0.014, this 
difference was less prominent upon culturing fibroblasts with B16F1 melanoma 
conditioned medium. Collagen type I transcript was similar in WT and Adam-9-/- 
fibroblasts in monoculture or when cultured with B16F1 conditioned medium (figure 
35).  
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Figure 35. Differential expression of ECM proteins in WT and Adam-9-/- fibroblasts. The 
expression of ECM proteins by fibroblasts with or without treatment with B16F1 conditioned 
medium (+B16F1 c.m.) was analyzed by RT-PCR and quantified by densitometry and 
normalized to S26 loading control and the fold change of transcript expression in Adam-9-/- 
versus WT fibroblasts was calculated. Water was used as negative control. Fibroblast; WT 
n=5, Adam-9-/- n=5, fibroblasts treated with B16F1 c.m. WT n=2, Adam-9-/- n=2.   
 
From these data, we conclude that the increased decorin protein, but not collagen 
type I, in fibroblasts from Adam-9-/- mice is a result of increase de novo synthesis. 
Collagen type I synthesis has been extensively studied and shown to be is regulated 
at multiple levels including mRNA synthesis and stability, protein synthesis and 
degradation (Bishop and Laurent 1995; Lindquist et al., 2000). As we did not observe 
any difference in collagen type I mRNA levels between Adam-9-/- and WT fibroblasts 
we speculate that the difference in collagen type I protein resulted from altered post-
translational events, for example, accumulation in Adam-9-/- fibroblast due to altered 
proteolysis in the absence of ADAM-9 protein. 
                                            
3.7 Cleavage of ECM proteins by ADAM-9 
3.7.1 Production of recombinant soluble ADAM-9 
Accumulation of collagen type I in Adam-9-/- fibroblasts supernatants which we have 
shown above (Figure 33 and 34), did not result from enhanced transcriptional activity 
(figure 35), but from post-translational events. ADAM-9 is an ECM degrading 
enzyme, shown to degrade fibronectin and laminin 111 (Schwettmann and 
Tschesche 2001), however both decorin and collagen type I have not been tested as 
possible substrates for ADAM-9. To find out whether ADAM-9 was involved in the 
cleavage of decorin and collagen type I, we produced recombinant soluble ADAM-9 
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proteins tagged with 6xHis and c-myc. Nucleotide sequence coding for ADAM-9 
soluble long (Adam-9s L) was amplified from cDNA derived from glioma cells. 
Proteolytic inactive form of this protein was produced by mutating the catalytic 
glutamic acid in the zinc binding motif to alanine by site-directed mutagenesis (see 
material and method section 2.2.5.1).  
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Figure 36. Purification of recombinant soluble ADAM-9. A, purification of ADAM-9 by metal 
affinity chromatography. B, detection of purified ADAM-9 in eluent by western blot using anti-
c-myc and anti-ADAM-9 antibodies. C, detection of soluble ADAM-9 in supernatant from 
COS-7 cells transfected with soluble ADAM-9 plasmid, with or without treatment with CMK. 
S; ADAM-9 soluble long, ADAM-9s L; mut., mutated form. 
 
The soluble Adam-9s L constructs were expressed in COS7 cells. Supernatants from 
transfected cells were collected and purified by size exclusion chromatography 
(figure 36A). Purified proteins were detected by western blot using anti-c-myc and 
anti-ADAM-9 antibodies. With both antibodies, we could detect a 86 KDa band 
corresponding to the inactive unprocessed form of ADAM-9 still containing the pro-
domain (figure 36B) and a 55 KDa band corresponding to the active processed form 
of ADAM-9 lacking the pro-domian. ADAM-9 is activated by removal of the pro-
domain by a furin-type pro-protein convertase in the secretory pathway (Roghani et 
al., 1999). To confirm that the 55 KDa band was the active processed form, we 
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treated transfected COS7 cells with a dec-RVKR-cmk furin inhibitor (Roghani et al., 
1999). After treating cells with furin inhibitor, ADAM-9 was detected only as a 86 KDa 
inactive unprocessed form (figure 36C), indicating that the 55 KDa band was the 
furin-activated form of ADAM-9.   
 
3.7.2 Degradation of proteins by ADAM-9  
The proteolytic activity of soluble ADAM-9s L was tested by gelatin zymography as 
previously shown (Schwettmann and Tschesche 2001), where ADAM-9 was detected 
as a gelatinolytic band of about 55 KDa (figure 37). A slight band was detected for 
the proteolytic inactive recombinant protein (mut. ADAM-9s L) indicating that the 
mutation did not lead to 100 % efficient blockage of proteolytic activity. To find out 
whether ADAM-9 has proteolytic activity towards decorin and collagen type I 
proteins, we have incubated them with either the proteolytic active or inactive 
recombinant ADAM-9s L in substrate buffer at 37°C overnight. Degradation of these 
proteins was analyzed by immunoblotting. Several bands of different sizes were 
generated when fibronectin was incubated with ADAM-9s L (figure 37). While no 
cleavage products were detected after incubation either with the mutated proteolytic 
inactive form of ADAM-9s L or with the substrate buffer alone, confirming the 
proteolytic activity of the recombinant ADAM-9s L and the previous results obtained 
by Schwettmann and Tscheche (2001). In case of decorin only the intact 40 KDa 
band was observed after incubation with soluble ADAM-9s L or mutated ADAM-9s L. 
A band of about 70 KDa was detected when collagen type I was incubated with 
ADAM-9s L and was absent when incubated with mutated ADAM-9s L or with 
substrate buffer alone (figure 37). The identity of this collagen fragment was 
confirmed by peptide mass fingerprint at the proteomic facility of the Center for 
Molecular Medicine, University of Cologne. 
These data indicate that ADAM-9 is not involved in the degradation of collagen type I 
since we could not detect differences in the total amount of the protein, but it may 
release a smaller fragment whose functional activity needs to be further investigated.  
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Figure 37.  ADAM-9 is involved in the degradation of ECM proteins. Analysis of the 
proteolytic activity of ADAM-9 soluble long (ADAM-9s L) by gelatin gel zymography under 
non-reducing conditions. Degradation of fibronectin, collagen type I and decorin by 
recombinant ADAM-9s L. 500 ng of each ECM protein was incubated with 1 µg/ml 
recombinant active ADAM-9s L or mutated inactive ADAM-9 soluble long (mut. ADAM-9s L). 
Proteolysis of recombinant proteins was analyzed by western blot. Recombinant proteins 
incubated in substrate buffer without the recombinant ADAM-9 was used as control. 
 
Another known substrate for ADAM-9 is the transmembrane collagen type XVII 
(Franzke 2002). In a previous study, we were able to demonstrate a role for ADAM-9 
in cutaneous wound healing. We have observed accelerated reepitheliazation in 
Adam-9-/- animals, because of increased migration of keratinocytes due to decreased 
shedding of collagen type XVII (Mauch et al. 2010). In vitro, primary keratinocytes 
lacking ADAM-9 also showed increased in migration. Expression of soluble active 
ADAM-9 constructs in Adam-9-/- mouse keratinocytes resulted in collagen type XVII 
shedding and rescued the migration phenotype observed (Mauch et al. 2010). 
Shedding of collagen type XVII was not observed when cells were transfected with 
catalytically inactivated ADAM-9 (Figure 38).  
 
Figure 38. Collagen type XVII is shedd 
by ADAM-9. Collagen type XVII 
shedding was restored by transient 
transfection of murine Adam-9-/- 
keratinocytes with the active but not 
inactivated (E>A) human ADAM-9. 
Actin was used as loading control. 
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3.7.3 Significance of collagen type I accumulation for melanoma progression 
We have shown that collagen type I is increased in Adam-9-/- fibroblast and at the 
tumor-stoma border of melanomas induced in Adam-9-/- mice (figure 32, 33 and 34). 
The functional significance of collagen type I accumulation at the tumor-stoma border 
for melanoma progression was established by assessing the proliferation of B16F1 
melanoma cells in the presence of different concentrations of collagen type I. 
Proliferation of B16F1 cells in the presence of increasing collagen type I 
concentration in culture was biphasic. Proliferation increased reaching a maximum 
when cells were cultured with 10 µg/ml collagen type I but decreased with further 
increase in collagen type I concentration (figure 39B). Thus, it is possible that the 
modest increase in collagen bundles at the tumor-stoma border in Adam-9-/- mice 
also contributed, in addition to TIMP-1 (3.5.4) to increase tumor cells proliferation, 
which we have found enhanced in these animals (3.3.3). This hypothesis is further 
corroborated by the detection of an increased number of actively proliferating (Ki67 
positive) tumor cells at the tumor periphery close to this ECM-rich matrix in vivo in 
Adam-9-/- as compared to WT mice (Figure 39A).               
                                           
Figure 39. Significance of collagen type I accumulation for B16F1 proliferation. A, tumor cell 
proliferation at the tumor periphery was assessed by detection of Ki67 nuclear protein. t, 
tumor; s, stoma; e, epidermis. Scale bar 200 µm. B, proliferation of B16F1 melanoma cells in 
the presence of collagen type I. The graph represents mean ± SD. p-values were calculated 
for cell proliferation in the presence of collagen type I compared to serum-free control. ∗ 
p<0.05.   
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3.8 ADAMs and MMPs in melanoma models  
The medaka spontaneous melanoma model offers another possibility for in vivo 
study of melanoma progression. We have analyzed the expression of Adams and 
Mmps in a spontaneous melanoma model generated in medaka (Meierjohann et al., 
2004). Our cooperation partner Svenja Meierjohann and Mannfred Schartl of 
Department of Physiological Chemistry I, University of Wurzburg, provided the tissue 
samples used in this study. We analyzed the mRNA expression of Adams and Mmps 
in RNA isolated from healthy skin, melanoma and yellow exophytic erythrophoreoma 
by RT-PCR (figure 40). Very low expression of all analyzed proteases, apart from 
Mmp-9, was detected in normal skin. A strong up-regulation of Adam-9, -10, and 
Mmp-13 and -14 were observed in melanoma and yellow exophytic erythrophoreoma 
as compared to healthy skin. Mmp-2 was only slightly up-regulated in melanoma but 
strongly up-regulated in yellow exophytic erythrophoreoma. Mmp-9 was strongly and 
equally expressed in healthy skin, melanoma and yellow exophytic erythrophoreoma, 
whereas Adam-12 was not detected in any tissue sample. In skin and melanoma, 
Adam-15 was similarly expressed and up-regulated in yellow exophytic 
erythrophoreoma. Adam-17 was detected in skin but absent in melanoma and yellow 
exophytic erythrophoreoma. Representative images of the RT-PCR analysis are 
shown in figure 40 below.  
 
   
 
Figure 40. Expression of Adams and 
Mmps in medaka melanoma model. RT-
PCR analysis of Adams and Mmps in 
medaka skin, melanoma and yellow 
exophytic erythrophoroma (y.e. ery.). 
Representative images showing 
transcript expression of Adams and 
Mmps (n=3; two sets of tissue). β-actin 
was used as control for mRNA integrity 
and equal loading. 
 
  Results 
     72  
The RT-PCR was quantified by densitometry and expression level of specific genes 
was normalized to β-actin to obtain the relative expression values. The expression 
ratio of each gene in melanoma and yellow exophytic erythrophoroma as compared 
to skin was calculated and presented in table 5 below. The expression of genes with 
ratios greater than 3 were set as “high” , ratios between 1 and 2 as “medium”, ratios 
less than 1 were considered “low”,  while ratios greater than 2.5 but less that 3 were 
considered “medium/high”. Adam-9, -10, Mmp-13 and -14 showed high expression in 
melanoma or yellow exophytic erythrophoroma as compared to skin. Adam-15 and 
Mmp-2 showed moderate expression in melanoma and yellow exophytic 
erythrophoroma as compared to skin. Mmp-9 showed medium/high expression while 
Adam-17 showed low expression in melanoma and yellow exophytic erythrophoroma 
as compared to skin.  
 
Table 5. Relative expression of Adams and Mmps in medaka melanoma model. 
high3.77high4.49MMP-14
high3.78high4.19MMP-13
Medium-high2.59Medium-high2.68MMP-9
medium1.95medium1.61MMP-2
low0.16low0.16ADAM-17
medium1.80-1.31ADAM-15
n.dn.dn.dn.dADAM-12
high5.41high6.10ADAM-10
high6.02high6.88ADAM-9
ExpressionRatio
yellow exophytic
erythrophoroma/skin
ExpressionRatio 
melanoma/skin
Gene
 
Low < 1; moderate 1-2; medium high >2.5; high > 3, - no difference, n.d, not detected 
 
Commercially available antibodies against medaka ADAMs and MMPs are rare. 
There however exist antibodies against ADAMs and MMPs antibodies, which were 
originally raised against human, or mouse and cross-react with the fish protein. e first 
analyzed the homology between human, murine and medaka ADAMs and MMPs and 
set up staining protocols using antibodies against mouse or human ADAMs and 
MMPs which have good cross reaction. Shown in table 6 below are the homologies 
between the different ADAMs and MMPs (complete protein) analyzed in the medaka 
melanoma model. The analysis was performed with Pairwise Alignment tool 
software; EMBOSS Needle, provided by The European Bioinformatics Institute (EBI). 
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Table 6. ADAMs and MMPs protein homology 
 % homology
646497MMP-14
585986MMP-13
57
72
56
47
74
75
59
human-medaka
5472MMP-9
7396MMP-2
5592ADAM-17
4140ADAM-15
6484ADAM-12
7693ADAM-10
5383ADAM-9
mouse-medakaHuman-mouse
 
 
To analyze the protein expression and localization of the genes in melanoma and 
yellow exophytic erythrophoroma as compared to skin was analyzed we have 
established immunoflourescence staining protocols testing several available 
antibodies. H&E staining was used to show an overview of the structures of the 
tissues (figure 41A). ADAM-9 was detected in the epidermis but not in the muscle of 
the healthy medaka skin (from fish trunk). In the invasive melanoma ADAM-9 staining 
was up-regulated and was predominantly expressed in the surrounding tumor stoma, 
little ADAM-9 was observed the exophytic erythrophoroma. In normal skin, ADAM-10 
was expressed in the epidermis and around the muscle fibers, and in both invasive 
melanoma and exophytic erythrophoroma; it was expressed in the tumor cells but 
showed very little stoma expression (figure 41B). MMP-13 was not detected in 
normal skin, melanoma nor in erythrophproma. MMP-14 was detected around the 
muscle fibers in the trunk. In invasive melanoma MMP-14 was localized in both tumor 
and stoma cells. In exophytic erythrophoroma, MMP-14 expression seems to be 
limited to the hyperplastic epidermis (figure 41B).  
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Figure 41 Expression of ADAMs and MMPs in medaka melanoma. A, H&E staining of, left, 
healthy trunk, middle, melanoma, right, yellow exophytic erythrophoroma (y.e. 
erythrophoroma). White squares indicate the areas shown in the immunofluorescence 
staining. Scale bar 25 µm. B, detection of ADAMs and MMPs in normal skin, melanoma and 
y.e. erythrophoroma. DAPI was used to stain the nuclei (blue). As negative control, sections 
were incubated without primary antibody. e, epidermis; m, muscle; h.e., hyperplastic 
epidermis, x.e., erythrophoroma; mel, melanoma. Scale bar 200 µm.                                                  
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4 Discussion  
Melanoma is the most aggressive type of skin tumor and can only be cured when 
diagnosed early and removed surgically before it metastasizes (MavKie et al., 2009). 
In melanoma progression, different proteolytic enzyme systems play important roles 
in degrading basement membranes, dermal matrices components, shedding 
adhesion molecules, and releasing growth factors and receptors (Airola et al., 1999; 
Duffy et al., 2011). ADAMs are a family of proteases which function in proteolysis and 
mediate cellular interaction (Mochizuki and Okada 2007). Several ADAMs are over-
expressed in cancers including melanoma (Mochizuki and Okada 2007). In this 
context, studies using cell lines and animal models have shown that ADAMs 
influence proliferation and invasion in vitro and tumor formation in vivo. For example; 
down-regulation of ADAM-17 in breast cancer cells using siRNA decreases tumor 
cell proliferation (Zheng et al., 2009) whereas knockout of ADAM-15 leads to reduced 
growth of heterotopically injected tumor cells in mice (Horiuchi et al., 2003). Recent 
investigation of our laboratory shows that ablation of ADAM-15 results in significantly 
reduced lung metastasis of melanoma (Schönefuss et al. 2012). In recent report, 
ADAM-9 was identified as a high-priority therapeutic target for human breast cancer 
(Chin et al., 2006). ADAM-9 is up-regulated in various human cancers such as renal, 
prostate, breast cancer and melanoma (O´Shea et al., 2003; Peduto et al., 2005; 
Zigrino et al., 2005; Fritzsche et al. 2008).  
ADAM-9 is ubiquitously expressed and is not essential during development, as mice 
lacking ADAM-9 are viable, fertile and do not have any major developmental defects 
(Weskamp et al., 2002). However, cone-rod dystrophy and retinal degeneration were 
detected in older Adam-9-/- mice (Parry et al., 2009). Using Adam-9-/- animals, we 
could show that upon skin injury ADAM-9 is involved in shedding of collagen XVII 
(figure 39) thereby modulating keratinocytes migration during re-epithelialization 
(Mauch et al., 2010).  
In a mouse model for prostate cancer, ADAM-9 was shown to play a causal role in 
the progression of tumor from well-differentiated to poorly-differentiated tumors; this 
was attributed to the ability of ADAM-9 to cleave EGF and FGFR2iiib (Peduto et al., 
2005). The adhesive function of ADAM-9 may play a role in mediating cell-cell 
interactions (Zigrino et al., 2011). Although the expression of ADAM-9 in melanoma 
has been analyzed its exact function in melanoma progression, whether it mediates 
cellular interactions between melanoma cells and stromal cells or whether it acts as a 
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proteolytic enzyme releasing cellular receptors or bound growth factors is yet 
unclear.   
 
4.1 Regulation of tumor development by ADAM-9 
In murine melanoma, we could detect ADAM-9 with a similar expression pattern as 
that observed in human melanoma namely, ADAM-9 was expressed at the tumor-
stoma border in both tumor and stromal cells (figure 8). In these areas, both direct 
and indirect cell-cell communication are ongoing to either counteract tumor 
development or support it by generating a permissive peritumoral environment. In 
vitro, ADAM-9 can mediate interaction of melanoma cells with stromal fibroblasts, 
and the absence of ADAM-9 expression on fibroblasts negatively influences the 
invasive capacity of melanoma cells (Zigrino et al., 2011). This indicates that the 
expression of ADAM-9 by the host may play a role in melanoma progression. When 
we grafted ADAM-9 expressing B16F1 cells into the flank of WT and Adam-9-/- mice 
we detected significantly larger tumors in the Adam-9-/- as compared to WT mice. 
Contrary to our results Guaiquil et al., 2009 reported reduced melanoma growth in 
Adam-9-/- mice compared to WT upon injection of B16F0 cells. However, when we 
grafted B16F0 cells or primary melanoma cells derived from the Hgf/Cdk4R24C mice, 
which spontaneously develop melanoma (Tormo et al., 2006), Adam-9-/- mice 
developed larger tumors compared to WT controls. Thus, we could show that 
increase growth of melanoma in the absence of Adam-9 was not a cell-type specific 
effect. We cannot absolutely exclude the effect of the background of the animals 
used for these studies however; there are some arguments eliminating the 
background as the reason for the differences between the two studies. First, the mice 
we have used were the same as those used by Guiaquill et al., (2009). These 
animals are of a mixed genetic background (129/SvJ and C57BL/6J). To reduce 
variations in the background and to increase the number of animals needed for the 
analysis, we have mated one pair of heterozygous Adam-9+/- parents to generate WT 
or Adam-9-/- mice. The offsprings of the heterozygous pairing were mated to get 
Adam-9-/- or WT mice that were closely related, as they were derived from the same 
heterozygous grandparents. Second, we failed to detect altered inflammatory 
reaction in tumors developed either in Adam-9-/- or WT mice to support an altered 
immunological reaction in response to the different genetic background. Differences 
that may account for these contradicting results can be technical differences in the 
  Discussion 
     77  
performance and analysis of the animal experiments. While Guaiquil et al., (2009), 
injected B16F0 cells subcutaneously and measured the weight of the tumors at the 
end of the experiment; we have injected melanoma cells intradermally and measured 
the volume of the tumors at different time points using a precision caliper. This raises 
the possibility that the contribution of ADAM-9 to the tumor progression is dependent 
on the injection site.   
Our data suggest a protective role of host-derived ADAM-9 during melanoma 
development. Protective functions of proteases have been reported for other ADAMs, 
for example, growth of subcutaneously injected B16F0 cells was significantly higher 
in Adam-8-/- mice compared to WT controls (Guaiquil et al., 2010). Apart from 
investigating angiogenesis in these tumors, this study does not address the reason 
for the increased tumor growth in Adam-8-/- mice. In addition, cell-specific expression 
of matrix metalloproteinases has been shown to have different effects on tumor 
growth. For example, the expression of MMP-12 by tumor cells (in this case 
squamous cell carcinoma) correlated with more aggressive and poorly-differentiated 
tumors, while its expression in macrophages correlated inversely with tumor 
invasiveness (Kerkelä et al., 2002).   
Key events that are known to influence tumor growth include angiogenesis (Ria et al., 
2010), inflammation (Coussens and Werb 2002), resistance to apoptosis and 
replicative potential (Hanahan et al., 2000). When we analyzed inflammatory reaction 
by determining the number and location of neutrophils, T-/B-cells and macrophages 
in tumors from Adam-9-/- and WT mice, we could not detect any alterations, 
suggesting that host-derived ADAM-9 is not involved in modulating inflammation. The 
function of ADAM-9 in inflammatory cells in the context of melanoma progression is 
unclear. However, up-regulation of ADAMs including ADAM-9 has been reported in 
peripheral blood mononuclear cells and macrophages during immune-mediated 
diseases where they are speculated to have a role in leukocyte migration by 
promoting cellular adhesion (Dehmel et al., 2007; Oksala et al., 2009). Interestingly, 
the expression of ADAM-9 in blood vessels coincides with that of CD31, where this 
protein was shown, by in vitro assays, to be involved in the shedding of proteins on 
the surface of endothelial cells (Guaiquil et al., 2009). In our tumor model, this 
function of ADAM-9 may not be relevant as despite detecting altered intratumoral 
angiogenesis in tumors from Adam-9-/- as compared to WT animals, comparison of 
vascularization in tumors of similar sizes (from different time point; day 6 Adam-9-/- 
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versus day 10 WT), displayed no difference in vessel density. This indicates that 
altered angiogenesis was a result of increased tumor growth but was not induced by 
the lack of ADAM-9 in the host. 
In vivo, we detected a significant increase in tumor cell proliferation accompanied by 
a decrease in apoptosis in tumors from Adam-9-/- as compared to those from WT 
animals. This difference was also observed when comparing tumors of similar sizes, 
albeit different excision time point. This indicates that the increase tumor cell 
proliferation and decreased apoptosis of melanomas in Adam-9-/- mice was due to 
Adam-9 ablation. We hypothesize that the resultant increased tumor development in 
the absence of Adam-9 is the result of an imbalance between tumor cell proliferation 
and apoptosis.  
 
4.2  Regulation of tumor metastasis by ADAM-9 
Another process, which we have investigated in our mouse model, was melanoma 
metastasis. Upon growth and migration from the primary site, melanoma cells 
metastasize to lymph nodes and distant organs. This process is underlined by 
several steps including intravasation, transport through the blood stream or lymph 
system, extravasation, arrest at the secondary site and growth (Koblinski et al., 2000; 
Tarhini and Agarwala 2006). The most common site of visceral metastasis is the 
lungs (Balch et al., 2003) while the regional lymph nodes are considered to be the 
first site of metastatic spread because they are the first to come in contact with the 
fluid draining from the primary tumor (Nathanson 2003). Despite the difference in 
tumor growth between Adam-9-/- and WT mice, there was no difference in metastasis 
to lungs and lymph nodes. In our melanoma grafting experiment, we observed similar 
metastasis to lungs and lymph nodes at day 3, 6 and 10. There was a slight 
decrease in metastasis to lungs and lymph nodes in Adam-9-/- mice at day 13, thus 
inversely correlating with tumor size. Tail vein injection of melanoma cells to assess 
metastasis of blood borne melanoma cells also did not show any difference in 
metastasis to lymph nodes and visceral organs. This suggests that the processes 
involved in metastasis such as chemotaxis, extravasation and intravasation were not 
affected by the loss of host-derived ADAM-9, and that despite the extensive growth 
of the tumors in Adam-9-/- mice, tumor growth and metastasis, are not strictly 
dependent on each other.  
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This is very important, but may consider controversial on the light of common 
theories of metastasis. Theories of metastasis have been recently revised, the 
parallel and the linear progression model. In the linear progression model, metastasis 
is generated by late dissemination of fully malignant cells after rounds of mutation 
and selection. The parallel progression model states that metastasis is initiated long 
before the primary tumor is diagnosed and is independent of the size of the tumor 
(reviewed by Klein 2009). The mouse mammary tumor virus-polyoma middle T 
antigen transgenic model (MMTV-PyMT) which develops spontaneous breast cancer 
(Hüseman et al., 2008) supports the parallel progression model. It was shown in this 
mouse models that disseminated tumor cells were present in the bone marrow and 
lungs when the primary tumor was in the premalignant phase, and that their number 
was independent of the size of the primary tumor (Hüsemann et al. 2008). 
Considering the parallel progression model it is not surprising that even though we 
detect large tumors, we observed similar metastatic spread to  lungs and lymph 
nodes in Adam-9-/- and WT mice.  
 
4.3  Melanoma cell proliferation and apoptosis in the absence of host-derived 
ADAM-9 
Cancer cells modify their pericellular stoma by producing a variety of factors (Mueller 
and Fusenig 2004). Fibroblasts constitute a great portion of the cellular part of the 
tumor stoma and contribute to tumor progression by secreting ECM components, 
proteases that modify the ECM and growth factors/cytokines (Kalluri and Zeisberg 
2006).  
ADAM-9 was shown to mediate cellular interactions between melanoma cells and 
fibroblasts (Zigrino et al 2011). To analyze the molecular mechanism, which may 
lead to altered tumor proliferation and apoptosis in the absence of Adam-9, we have 
therefore focused our studies on the role of fibroblasts-derived ADAM-9 in these 
processes. Using co-culture system of tumor cells and fibroblasts, we could show 
that direct contact of mitotically inactive fibroblasts and melanoma cells alone do not 
influence cell proliferation. Induction of B16F1 cell proliferation was observed when 
melanoma cells were cultured with Adam-9-/- fibroblasts either in transwell or in using 
Adam-9-/- fibroblast supernatant suggesting a soluble-factor mediated mechanism. 
Interestingly, conditioned media from Adam-9-/- fibroblasts could enhance the 
proliferation of human melanoma and glioma cells, whereas no significant effect was 
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detected on epithelial tumor cell lines. The effect on glioma cells could be because 
glioma and melanoma share many similar biological properties as melanocytes and 
glial cells share a common origin namely the precursor cell type, which differentiate 
from neural crest cells in the dorsolateral surface (Herlyn et al., 2000). Melanoblast 
precursors can differentiate into glial precursors and glioblasts can differentiate into 
melanoblasts (Herlyn et al., 2000; Adameyko et al., 2010).  
Studies have documented the regulation of tumor cell proliferation by stromal 
fibroblasts. For example, serum-free media from breast fibroblasts stimulate the 
proliferation of breast cancer cell lines; an effect attributed partly to insulin-like growth 
factors (Kees et al., 1996). Another study ascribed the growth promoting activity of 
stromal fibroblasts towards breast carcinoma to their ability to secrete stromal cell-
derived factor 1 which stimulates tumor growth directly through its receptor, CXCR4 
(Orimo et al., 2005). 
We analyzed factors present in the supernatant of fibroblasts and tumor lysates from 
Adam-9-/- and WT mice and selected factors which were regulated in both, thereby 
likely derived from fibroblasts. We identified several soluble factors with roles in 
apoptosis and growth stimulating activity. Among soluble factors with growth 
stimulatory activity on melanoma cells were macrophage inflammatory protein -2 
(MIP-2/CXCL1) also known as growth-regulated oncogene (Haghnegahdar et al., 
2000), stromal cell-derived factor 1 alpha (SDF-1α/CXCL12) (Lui et al., 2011) and 
TIMP-1 (Hayakawa et al., 1992). However, the most significantly regulated factor was 
TIMP-1, which was up-regulated 6.72 fold in Adam-9-/- fibroblasts and 7.91 fold in 
tumor lysates from Adam-9-/- mice. We could detect increased Timp-1 transcript and 
protein in fibroblasts from Adam-9-/- mice in vitro as well as in the stoma surrounding 
the melanoma tumors in vivo. This protein has been described to have both tumor 
promoting and tumor suppressing activities that could be metalloproteinase-
independent or metalloproteinase-dependent (Hornebeck et al., 2005).  
TIMP-1 has been shown to possess growth promoting activity for a number of cells 
(Hayakawa et al., 1992; Sorensen et al., 2008). Its growth promoting activity may 
explain its presence of the serum used for cell culture (Hayakawa et al., 1992). In a 
human melanoma cell line, the expression of TIMP-1 has been shown to stimulate 
growth (Hoashi et al., 2001). Neutralization of TIMP-1 in media from Adam-9-/- 
fibroblasts ablated the increased induction of B16F1 melanoma cell proliferation 
observed. The growth promoting activity of TIMP-1 was further strengthened by the 
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fact that, in vitro we could show that recombinant TIMP-1 enhances the growth of 
murine and human melanoma cells. Conflicting views exists on the role of TIMP-1 in 
tumor growth; TIMP-1 transgenic mouse model, over-expressing TIMP-1 in the liver, 
showed early subcutaneous growth of melanoma with increased tumor angiogenesis 
(De Lorenzo et al., 2003). On the other hand, up-regulation of TIMP-1 in B16F10 
melanoma cells was shown to suppress tumor growth (Khokha 1994). This implies 
that TIMP-1 may have a promoting or inhibiting effect on melanoma growth 
depending on the cellular source or local and systemic expression. TIMP-1 can 
regulate cell growth in an MMP-dependent and MMP-independent manner. MMP-
independent function of TIMP-1 occurs through binding of TIMP-1 to a cell surface 
receptor, CD63, which is a member of the tetraspanin family (Jung et al., 2006). 
Binding of TIMP-1 to a CD63/integrin β1 complex is thought to activate integrin-
mediated signaling pathway involving focal adhesion kinase, phosphoinositide 3-
kinase, extracellular signal-regulated kinase-1 and Akt leading to the regulation of 
cell proliferation and cell survival (Chirco et al., 2006). It is however unclear whether 
the proliferative effect of TIMP-1 we detected on B16F1 cell proliferation is mediated 
by an MMP-dependent or independent manner. The increase in TIMP-1 we observed 
is possibly due to increase IL-6 and IL-1, which have been shown to induce the 
synthesis of TIMP-1 (Richard et al., 1993). Both cytokines were up-regulated in 
fibroblasts and tumors from Adam-9-/- animals.  
In addition to increased proliferation in melanoma grown in Adam-9-/- mice, we also 
detected a significant reduction in B16F1 cell apoptosis. Although TIMP-1 also has 
anti-apoptotic activity (Stetler-Stevenson 2008), neutralization of TIMP-1 in media 
from Adam-9-/- fibroblasts prior to B16F1 stimulation did not affect apoptosis. In 
fibroblasts supernatants and tumor lysates, we identified factors that could modulate 
apoptosis, such as soluble TNF-α and soluble TNFRI. TNF-α is a cytokine secreted 
by a variety of cells and signals through two surface receptors, TNFRI and TNFRII. 
The majority of the biological activity of TNF-α is mediated through binding to TNFRI 
(Chen and Goeddel 2002). Binding of membrane bound or soluble form of TNF-α, 
released by shedding (Garton et al., 2006), to TNFRI leads to the activation of pro-
apoptotic signaling or expression of anti-apoptotic genes (Baud and Karin 2001). 
Proteolytic release of TNFR1 generates a soluble receptor (sTNFRI) which binds to 
TNF-α and inactivates the receptor-mediated signaling (Engelmann et al., 1989). We 
hypothesize that in the absence of ADAM-9 increased sTNFRI neutralizes TNF-α 
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resulting in reduced melanoma cell apoptosis. In support of this hypothesis, inhibition 
of TNFRI shedding in Adam-9-/- fibroblasts, prior to melanoma cell stimulation, led to 
reduced release of TNFRI and increased apoptosis. Furthermore, addition of Enbrel, 
a recombinant human soluble TNF-α receptor II which is capable of binding TNF-α 
(Madhusudan et al., 2005), to supernatants from WT fibroblasts also leads to 
reduced apoptosis. These data confirmed that sTNFRI is responsible for the reduced 
level of apoptosis observed in B16F1 cells upon culture with media of Adam-9-/- 
fibroblast.  
sTNFRI derives from ectodomain shedding by the activity of ADAM-10 and ADAM-17 
(Hikita et al., 2009), however, ADAM-17 has been indicated as the main sheddase 
for the TNFR1 (Bell et al., 2007). We found ADAM-10 and ADAM-17 up-regulated in 
fibroblasts from Adam-9-/- animals suggesting that the increase in sTNFRI maybe due 
to the activity of these proteases. The increase of sTNFR1 may be due to increase of 
ADAM-17 rather than ADAM-10 as ADAM-10, but not ADAM-17, is effectively 
inhibited by TIMP-1 (Amour et al., 2000), which is increased in Adam-9-/- fibroblasts. 
Inhibition of ADAM-17 in Adam-9-/- fibroblasts with TAPI-0 led to a reduction of 
sTNFRI release. TAPI-0 is not specific for the inhibition of ADAM-17 alone but also 
inhibits MMPs such as MMP-1, -3, -9 and -13 (Roghani et al., 1999). However, 
among these MMPs only MMP-9 is thought to be involved in the shedding of TNFRI 
(Masters Thesis; http://www.rescancer.com/bmc-cancer/20570.html). Furthermore 
TAPI-0 has a higher binding affinity to MMP-9 than to ADAM-17 (Ki values ADAM-17, 
8.8 nM; MMP-9 0.5 nM) (Roghani et al., 1999). Despite the fact that we cannot 
conclusively point to ADAM-17 in releasing TNFR1 upon Adam-9 knock out in 
fibroblasts, all together our data support the hypothesis that the decrease in B16F1 
apoptosis after stimulation with Adam-9-/- fibroblast supernatants is the result of 
increased enzymatic release of sTNFRI. Interestingly, TNF-α, which we have found 
increased in fibroblasts and melanomas from Adam-9-/- mice, can induce the 
expression of ADAM-17 (Cessaro et al., 2009), thus suggesting an autocrine 
regulatory path leading at the end to modulation of apoptosis.  
It is still unclear how the lack of ADAM-9 affects the production of cytokines and other 
soluble factors. ADAM-9 may influence the production of cytokines through signaling 
via its cytoplasmic tail. The cytoplasmic tail of ADAM-9 has already been 
documented in the regulation of inside-out signaling where binding of ADAM-9 to 
PKCδ triggers spatial changes in ADAM-9 and affects the shedding of HB-EGF 
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(Izumi et al., 1998). In addition, the cytoplasmic tail of ADAM-9 contains two proline-
rich sequences, which bind SH3 domains. SH3 domains are is present in several 
signaling molecules (Weskamp et al., 1996; Pawson 1995). One can speculate that 
ADAM-9 may interact with SH3 domain-containing signaling molecules in the 
cytoplasm and in this way influence intracellular signaling, leading to regulation of 
various soluble factors. Possibly, in the absence of ADAM-9 lack of shedding of cell 
surface proteins may affect the production of cytokines. One candidate surface 
protein is delta-like 1 (Dll1). Dll1 is a notch ligand that is constitutively cleaved by 
ADAM-12 and ADAM-9 (Dyczynska et al., 2007). When Dll1 binds to notch, the 
ligand bound receptor undergoes proteolytic cleavage in the extracellular and 
transmembrane domain. The intracellular domain translocates to the nucleus and 
regulates gene expression (Lai 2004). We could envision that in the absence of 
ADAM-9 reduced ligand processing may lead to increase notch ligand-receptor 
interaction and increase notch signaling. Indeed, persistent notch signaling has been 
shown to affect fibroblasts gene expression (Dees et al., 2011). We found a 
drosophila homolog of Dll1, Dlk1, significantly up-regulated in Adam-9-/- fibroblast 
rendering the above speculation feasible. Detailed analysis of this theory was not 
possible within the frame of this thesis; further investigations are aimed at analyzing 
the expression and cleavage of Dll1 in Adam-9-/- versus WT fibroblasts. RNA array 
analysis has identified transcription factors, which are differentially expressed in the 
absence of ADAM-9 and may be involved in the synthesis of cytokines. One of the 
transcription factors up-regulated in Adam-9-/- fibroblasts is trans-acting transcription 
factor 6 (Sp6) also known as Krueppel-like factor 14, a member of the Sp/KLF family 
of transcription factors (Kacynski et al., 2003). A member of this family, Sp1, is 
involved in the regulation of TIMP-1 and ADAM-17 (Lee et al., 2004; Szalad et al., 
2009). Whether Sp6 is also involved in the regulation of TIMP-1 or ADAM-17 or other 
cytokines and whether it is itself regulated by ADAM-9 remains to be validated.   
 
4.4  Extracellular matrix proteins in the absence of ADAM-9 
The ability of tumor cells to grow and invade the surrounding tissue depends on their 
ability to communicate with other cells of the tumor microenvironment and to remodel 
the extracellular matrix (ECM) (Liotta and Kohn 2001). Remodeling of the ECM by 
proteases alters the matrix and also sets bound growth factors and cytokines free 
thereby contributing to the regulation of cellular functions such as adhesion, 
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proliferation and migration (Van Kempen et al., 2003; De wever and Mareel 2003). 
Proteolytic activity of ADAM-9 towards matrix components such as laminin 111 and 
fibronectin have been reported (Schwettman and Tschesche 2001; Mazzocca et al., 
2005), therefore, we started to explore by proteomic analysis how the enzymatic 
activity of ADAM-9 may modify the ECM at the tumor-stroma border. 
 Analysis of matrix purified from the peritumoral stroma area of tumors from WT and 
Adam-9-/- animals, revealed differential expression of some ECM proteins and 
cellular components, the latter was due to the presence of peritumoral cells in the 
analyzed specimen. ECM proteins such as decorin, collagen type V and collagen 
type I were up-regulated at the tumor-stroma border of tumors from Adam-9-/- mice. 
The up-regulation of both collagen type I and V, is somehow not surprising as 
collagen type V has been often associated with collagen type I and is involved in 
fibrillogenesis (Wenstrup et al., 2004). Increased collagen type V has been 
associated with the promotion of epidermal tumors (Marian 1987), but a role for this 
collagen in melanoma development has not been explored. Increase synthesis of 
collagen type I by stromal cells has been reported in melanoma (Smolle et al., 1996).   
In skin, fibroblasts are the major cell types that synthesize collagen type I and other 
ECM components (Kielty et al., 1993). In vitro, analysis of fibroblasts or fibroblasts 
stimulated with murine melanoma cells media confirmed increase in collagen type I 
and decorin secretion. No changes were detected in the other analyzed matrix 
proteins. Further investigations showed that decorin but not collagen type I was 
transcriptionally induced in Adam-9-/- fibroblasts, indicating that increase of decorin 
was as a result of increased de novo synthesis. However, the increase in decorin 
protein secretion by fibroblasts alone is too small to account for the 2-fold increase 
we observe at the tumor-stroma border in tumors from Adam-9-/- mice. Other cell 
types for example endothelial cells (Järveläinen et al., 1992) could therefore be 
involved in the secretion of decorin in vivo. As decorin is involved in collagen 
fibrillogenesis (Weber et al., 1995; Iozzo et al., 1998), it is tempting to speculate that 
its expression is increased to reorganize the increasingly secreted collagen type I.  
In the case of collagen type I, its production was not regulated at the transcriptional 
level indicating that post-transcriptional mechanisms are involved. Increased collagen 
type I in vivo and in vitro, may result from decreased degradation. Some MMPs 
known to degrade collagen type I e.g. MMP-13 (Nagase and Murphy 2008), can be 
inhibited by the high amount of TIMP-1 present in the peritumoral areas when ADAM-
  Discussion 
     85  
9 is ablated. However, this would not explain an ADAM-9-dependent proteolytic 
effect, as ADAM-9 is not inhibited by TIMP-1 (Amour et al., 2002). Apart from the 
accumulation of collagen type I in Adam-9-/- fibroblasts, another interesting 
observation was the significant reduction of a low molecular weight fragment of 
collagen type I of about 70KDa in Adam-9-/- fibroblasts. Enzymatic assays using 
recombinant ADAM-9 indicated that active soluble ADAM-9 but not its proteolytically 
inactive form could cleave collagen type I generating a fragment of about 70KDa. 
Mass peptide finger printing identified this fragment as a fragment of collagen alpha 1 
(I) chain. Whether this fragment is of biological significance will be a matter of future 
investigations. Although ADAM-9 could cleave collagen type I, the amount of intact 
collagen type I was not visibly reduced (figure 37). This could mean that the 
accumulation of collagen type I in fibroblasts and melanoma from Adam-9-/- mice is 
because of reduced expression of other collagenases or increase expression of 
collagenase inhibitors in the absence of ADAM-9. 
In a study using an in vitro model that reconstitutes the fibrillar collagen type I 
structure, Henriet et al., (2000) showed that the proliferation of melanoma cells in 
contact with collagen was dependent on the organization of the collagen fibrils. High 
collagen type I density also enhances the growth of mammary tumors (Provenzano 
et al., 2008). Furthermore, interaction of melanoma cells with collagen type I have 
been shown to reduce drug-induced apoptosis (reviewed by Aoudjit and Vuori 2012). 
In agreement with this, in vivo analysis of B16F1 cell proliferation in tumors from 
Adam-9-/- animals showed higher number of proliferating melanoma cells at the tumor 
periphery, in close vicinity to areas with high collagen density compared to tumors 
from WT. In support of a pro-proliferative activity of collagen type I we could also 
demonstrate in vitro, that B16F1 melanoma cell proliferation is increased with 
increase collagen type I concentration reaching a plateau above which proliferation 
reduces steadily. Higher amount of collagen type I may lead to the formation of 
networks around the tumor cells, which are too stiff or tense and impede cell 
proliferation. Changes in the stiffening of the ECM are observed in the progression of 
cancer (Butcher et al., 2009; Levental et al., 2009). Matrix stiffness plays a role in cell 
proliferation; this may depend on the type of cancer as glioma cells were shown to 
proliferate more on rigid ECM possibly by altering the mechanochemical feedback 
during mitosis hence altering the cells progression through the cell cycle (Ulrich et al., 
2009). Another explanation is that stiff matrix triggers mitogenic signaling pathways 
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through integrins (Paszek et al., 2005).  The increased tumor cell proliferation maybe 
the result of two events; increased TIMP-1 and collagen type I at the tumor-stroma 
border.  
In summary, we showed that the expression of ECM components during melanoma 
development is altered in the absence of ADAM-9. We observed increase expression 
of decorin and collagen type I at the tumor-stroma border of melanomas from Adam-
9-/- animals and in vitro in Adam-9-/- dermal fibroblasts. We identified collagen type I 
as a new ADAM-9 substrate and provide evidence that the collagen type I 
concentration is important in B16F1 melanoma development.  
 
4.5  Melanoma fish model 
Among models available for the study of melanoma, a few spontaneous mouse 
models have been characterized (Pollock et al., 2003; Tormo et al., 2006) and the 
addition of spontaneous fish models has enlarged the possibilities for in vivo studies. 
Fish models for melanoma include the Xiphophorus model (Meierjohann et al., 2004); 
the zebrafish model (Patton et al., 2005) and the medaka model (Meierjohann et al., 
2004). The Medaka fish melanoma model spontaneously develops tumors in the 
pigment cells due to over-expression of Xmrk receptor under control of a pigment cell 
specific promoter (Meierjohann et al., 2004). Some molecular peculiarities of human 
and murine melanoma have been characterized in this model (Meierjohan and 
Schartl 2006). Although MMPs and ADAMs have been identified in the medaka 
genome (http://www.ensembl.org/Oryzias_latipes/Info/Index) their characterization in 
skin and melanoma in terms of expression and function has not been investigated. 
One aspect we investigated in this study was the expression of proteolytic enzymes, 
which are necessary to generate an environment that helps tumor cells to invade the 
surrounding tissue and to cross physical barriers (Stewart et al., 2004). We have 
analyzed the expression and localization of various metalloproteinases in medaka 
melanoma tissue as compared to healthy unaffected skin. We have shown increased 
expression of Adam-9, -10, Mmp-2, -13 and -14, specifically in melanoma and 
exyophytic erythrophoroma as compared to healthy skin at transcript level. Similar to 
human melanoma (Zigrino et al., 2005) we have detected ADAM-9 protein in the 
stoma compartment in medaka melanoma (figure 41). ADAM-10 was highly 
expressed in medaka melanoma cells, likewise in human melanoma (Lee at al., 
20010). MMP-14 was localized in tumor and stromal cells, an expression pattern, 
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which resembles that observed in humans (Anderegg et al., 2009). Other 
metalloproteases, which have been shown to be expressed in melanoma like ADAM-
12, -15, -17 and MMP-13 were not detected with the antibodies used, probably due 
lack of cross-react with this specie.  
We show here for the first time the expression pattern of some metalloproteases in a 
melanoma spontaneously developed in fish. The similarities in the expression pattern 
of the ADAMs and the MMPs in the medaka and human melanoma makes the 
medaka melanoma model a promising tool for the analyzing the expression and role 
of metalloproteases in melanoma progression and screening of metalloprotease 
inhibitors.  
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5 Conclusion and perspectives 
This study provides insight into the molecular mechanisms involved in the regulation 
of tumor growth and modification of the peritumoral microenvironment by fibroblast-
derived ADAM-9. This is important as it shows that proteases may exert functions 
that may be beneficial to counteract cancer. We provide data showing that during 
melanoma development, stroma-derived ADAM-9 is involved in the regulation of 
TIMP-1 and sTNFR1 in fibroblasts, which in turn affect tumor cell proliferation and 
apoptosis. The mechanism of how ADAM-9 regulates the production of cytokines is 
still unclear; whether it involves cleavage of a cell surface protein which then affects 
downstream signaling or whether it involves signaling through its cytoplasmic tail will 
be addressed in future studies. The use of recombinant ADAM-9 with specific 
deletion of the metalloprotease domain or cytoplasmic tail in cell base assays will 
indicate which domain is important in the regulation of cytokines by ADAM-9.  
Enhanced tumor growth in Adam-9-/- mice was accompanied by accumulation of 
collagen type I around the tumors.  The fact that collagen type I enhances tumor cell 
proliferation in a concentration dependent manner, depicts the significance of the 
composition and integrity of the ECM in controlling growth of tumor cells. ADAM-9 
could cleave and released a 70 KDa fragment from collagen type I, which represents 
a new ADAM-9-proteolytic product. 
In a side project, we show that the expression profile of MMPs and ADAMs in the 
medaka melanoma is similar to that of human melanoma, providing a new model for 
the future study of metalloproteases in melanoma progression.   
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Abbreviation 
ADAM   a disintegrin and metalloprotease domain 
BSA   bovine serum albumin 
cDNS   complimentary deoxyribonucleic acid 
c.m.   conditioned medium 
Dll1   delata-like 1 
DNA   deoxyribonucleic acid 
dNTP   2’-Deoxynucleosine-5’-triphosphate 
EDTA   ethylenediamine tetraacetic acid 
ERE   estrogen response element 
FCS   fetal calf serum 
g   gram 
H&E   hematoxylin and eosin 
IF   immnunofluorescence 
IHC   immunohistochemistry 
IL   interleukin 
kDa   kilodalton 
NGS   normal goat serum 
No.   number 
M   meter 
mM    millimolar 
mm   millimetre 
Mmp   matrix metalloproteinase 
nm   nanometer    
PFA   parafomaldehyde 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction  
RNA   ribonucleic acid 
rpm   rounds per minute 
RT   reverse transcriptase 
SD   standard deviation 
SDS   sodium dodecylsulphate 
SDS-PAGE  denaturant polyacrylamide gel electrophoresis 
TIMP   tissue inhibitor of metalloprotease 
TNF-α   tumor necrosis factor alpha 
TNF RI   tumor necrosis factor receptor type I 
TNF RII   tumor necrosis factor receptor type II 
Tris    tri (hydroxymethyl)-aminomethane 
U   unit 
v/v    volume percentage 
w/v   weight percentage 
WB   western blot 
WT   wild type 
µ   micro 
° C degrees centigrade 
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